

117TH CONGRESS  
1ST SESSION

**S.** \_\_\_\_\_

To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety  
of cosmetics.

---

IN THE SENATE OF THE UNITED STATES

Mrs. FEINSTEIN introduced the following bill; which was read twice and  
referred to the Committee on \_\_\_\_\_

---

**A BILL**

To amend the Federal Food, Drug, and Cosmetic Act to  
ensure the safety of cosmetics.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 (a) **SHORT TITLE.**—This Act may be cited as the  
5 “Personal Care Products Safety Act”.

6 (b) **TABLE OF CONTENTS.**—The table of contents for  
7 this Act is as follows:

Sec. 1. Short title; table of contents.

**TITLE I—COSMETIC SAFETY**

Sec. 101. Registration of cosmetics facilities and cosmetic ingredient state-  
ments.

Sec. 102. Review of ingredients and non-functional constituents.

- Sec. 103. Good manufacturing practices for cosmetics.
- Sec. 104. Adverse event reports.
- Sec. 105. Records inspection; mandatory recall authority.
- Sec. 106. Labeling.
- Sec. 107. Coal tar chemicals.
- Sec. 108. Fragrance allergen disclosure.
- Sec. 109. Sense of the Senate on animal testing.
- Sec. 110. Preemption.
- Sec. 111. Reporting.
- Sec. 112. Small businesses.
- Sec. 113. Applicability with respect to certain cosmetics.
- Sec. 114. Enforcement.
- Sec. 115. Consumer information.
- Sec. 116. Ban on perfluoroalkyl or polyfluoroalkyl substances.
- Sec. 117. Counterfeit cosmetics.

#### TITLE II—FEES RELATED TO COSMETIC SAFETY

- Sec. 201. Findings.
- Sec. 202. Authority to assess and use cosmetic safety fees.
- Sec. 203. Direct hiring authority to support activities related to cosmetics.

## 1       **TITLE I—COSMETIC SAFETY**

### 2   **SEC. 101. REGISTRATION OF COSMETICS FACILITIES AND** 3                   **COSMETIC INGREDIENT STATEMENTS.**

4           (a) AMENDMENTS.—Chapter VI of the Federal Food,  
 5 Drug, and Cosmetic Act (21 U.S.C. 361 et seq.) is amend-  
 6 ed by adding at the end the following:

#### 7   **“SEC. 604. DEFINITIONS.**

8           “In this chapter:

9                   “(1) COSMETIC FORMULATION.—The term ‘cos-  
 10           metic formulation’ means a preparation of cosmetic  
 11           raw materials with a qualitatively and quantitatively  
 12           set composition.

13                   “(2) COSMETIC PRODUCT.—The term ‘cosmetic  
 14           product’ means a preparation of cosmetic raw ingre-  
 15           dients, which may come in a range of possible  
 16           amounts for each ingredient, for purposes of intro-

1       duction into interstate commerce as a finished prod-  
2       uct.

3           “(3) FACILITY.—The term ‘facility’ includes  
4       any factory, warehouse, or establishment (including  
5       a factory, warehouse, or establishment of an im-  
6       porter) that manufactures or processes cosmetic  
7       products or cosmetic formulations, or any other enti-  
8       ty whose name and address appear on the label of  
9       a cosmetic product. Such term does not include—

10           “(A) beauty shops and salons that do not  
11       otherwise manufacture, process, or package cos-  
12       metics at that location;

13           “(B) cosmetic product retailers, including  
14       individual sales representatives, direct sellers,  
15       retail distribution facilities, and pharmacies,  
16       that do not otherwise manufacture, process, or  
17       package cosmetics at that location;

18           “(C) hospitals, physicians’ offices, and  
19       health care clinics;

20           “(D) public health agencies and other non-  
21       profit entities that provide cosmetics directly to  
22       the consumer;

23           “(E) hotels and other entities that provide  
24       complimentary cosmetics to guests;

1           “(F) trade shows and other venues where  
2           cosmetic product samples are provided free of  
3           charge;

4           “(G) a factory, warehouse, or establish-  
5           ment of—

6                   “(i) domestic manufacturers with less  
7                   than \$500,000 in average gross annual  
8                   sales of cosmetic products in the United  
9                   States for the previous 3-year period, or  
10                  less than \$1,000,000 in such sales of cos-  
11                  metic products produced in a private resi-  
12                  dence; or

13                   “(ii) entities that manufacture or  
14                   compound cosmetic products solely for use  
15                   in research, teaching, or pilot plant pro-  
16                   duction and not for sale; or

17           “(H) an establishment that solely performs  
18           one or more of the following with respect to cos-  
19           metic products: labeling, relabeling, packaging,  
20           repackaging, holding, or distributing.

21           “(4) FOREIGN FACILITY.—The term ‘foreign fa-  
22           cility’ means a facility that manufactures or proc-  
23           esses a cosmetic formulation or cosmetic product  
24           that is exported to the United States without further  
25           processing or packaging inside the United States. A

1 cosmetic is not considered to have undergone further  
2 processing or packaging for purposes of this defini-  
3 tion solely on the basis that labeling was added or  
4 that any similar activity of a de minimis nature was  
5 carried out with respect to the cosmetic.

6 “(5) NON-FUNCTIONAL CONSTITUENT.—The  
7 term ‘non-functional constituent’ means any sub-  
8 stance that is an incidental component of an ingre-  
9 dient, a breakdown product of an ingredient or a by-  
10 product of the manufacturing process that has not  
11 been intentionally added as a separate substance and  
12 serves no technical function in the cosmetic.

13 “(6) RESPONSIBLE PERSON.—The term ‘re-  
14 sponsible person’ means—

15 “(A) the brand owner who is the domestic  
16 or foreign manufacturer or entity whose name  
17 appears on a cosmetic product label of a cos-  
18 metic product distributed in the United States,  
19 except for entities described in subparagraphs  
20 (A) through (H) of paragraph (3); or

21 “(B) a contract manufacturer who provides  
22 cosmetic products to the entities described in  
23 subparagraphs (A) through (H) of paragraph  
24 (3).”.

1 **“SEC. 605. REGISTRATION OF COSMETIC FACILITIES.**

2 “(a) REGISTRATION AND FEES FOR EXISTING MAN-  
3 UFACTURING OR PROCESSING OF COSMETICS.—

4 “(1) REGISTRATION, IN GENERAL.—Not later  
5 than 1 year after the date of enactment of the Per-  
6 sonal Care Products Safety Act, and at a similar  
7 time in each subsequent year, as determined by the  
8 Food and Drug Administration, each responsible  
9 person engaged in manufacturing or processing a  
10 cosmetic product or a cosmetic formulation distrib-  
11 uted in the United States shall register all of the re-  
12 sponsible person’s facilities with the Food and Drug  
13 Administration.

14 “(2) FEES.—If the average gross annual sales  
15 in the United States of cosmetic products of all of  
16 the responsible person’s facilities registered under  
17 paragraph (1) for the previous 3-year period is  
18 greater than \$10,000,000, a registration shall not be  
19 complete under this subsection until the responsible  
20 person has paid any registration fee required under  
21 section 7440.

22 “(b) REGISTRATION BY NEW FACILITIES.—Any fa-  
23 cility first engaging after the date of enactment of the Per-  
24 sonal Care Products Safety Act in an activity that would  
25 require it to register under subsection (a) shall register  
26 with the Food and Drug Administration within 60 days

1 of first engaging in such activity, and thereafter in accord-  
2 ance with subsection (a).

3 “(c) CONTRACT MANUFACTURERS.—If a facility  
4 manufactures or processes cosmetic products on behalf of  
5 a responsible person, the Food and Drug Administration  
6 shall require only a single registration for such facility  
7 even if such facility is manufacturing or processing its own  
8 cosmetic products or cosmetic products on behalf of more  
9 than 1 responsible person. Such single registration may  
10 be submitted to the Food and Drug Administration by  
11 such facility or any responsible person whose products are  
12 manufactured or processed at such facility.

13 “(d) CHANGES TO INFORMATION.—A registrant who  
14 has submitted a registration under this section shall notify  
15 the Food and Drug Administration of any change to the  
16 information required under subsection (a) or (b) not later  
17 than 60 days after the date of such change, unless other-  
18 wise specified by the Food and Drug Administration.

19 “(e) FORMAT; CONTENTS.—

20 “(1) ELECTRONIC FORMAT.—Each registration  
21 shall be submitted using an electronic format, as  
22 specified in a registration form provided by the Food  
23 and Drug Administration.

24 “(2) CONTENTS.—

1                   “(A) IN GENERAL.—Except as provided in  
2                   subparagraph (B), the registration shall contain  
3                   the following information:

4                   “(i) Each facility’s name and full ad-  
5                   dress, identifying the precise physical loca-  
6                   tion of the facility.

7                   “(ii) The identity of the facility, in-  
8                   cluding the unique facility identifier, if  
9                   any, previously assigned by the Food and  
10                  Drug Administration to the facility under  
11                  subsection (h).

12                  “(iii) All business trading names used  
13                  by the facility.

14                  “(iv) The product category or cat-  
15                  egories of each cosmetic product or cos-  
16                  metic formulation manufactured or proc-  
17                  essed at the facility or on whose label the  
18                  facility’s name and address appear.

19                  “(v) The type of activity conducted at  
20                  the facility (such as manufacturing or  
21                  processing).

22                  “(vi) The name, title, street address,  
23                  telephone number, and electronic contact  
24                  information of the emergency contact for  
25                  the facility.



1           “(vii) In the case of a foreign facility,  
2           the name, street address, telephone num-  
3           ber, emergency contact information, and  
4           name of the United States agent for the  
5           facility, and, if available, the electronic  
6           contact information of the United States  
7           agent.

8           “(viii) The name, title, street address,  
9           telephone number, and electronic contact  
10          information of the individual submitting  
11          the registration.

12          “(ix) An assurance that the Food and  
13          Drug Administration will be permitted to  
14          inspect such facility at the times and in  
15          the manner permitted by this Act.

16          “(x) Additional information pertaining  
17          to the facility or to the cosmetic products  
18          or cosmetic formulations manufactured or  
19          processed at the facility, or on whose label  
20          the facility’s name and address appear, in-  
21          cluding all brand names known to con-  
22          sumers, as the Food and Drug Administra-  
23          tion may require by regulation.

24          “(xi) An ingredient listing for all cos-  
25          metic products manufactured or processed

1 in such facility, in accordance with sub-  
2 section (f), which, for each relevant cos-  
3 metic product, may be submitted to the  
4 Food and Drug Administration as part of  
5 such registration or separately.

6 “(xii) A written assurance that each  
7 cosmetic product manufactured or proc-  
8 essed in such facility has been substan-  
9 tiated for safety or carries the warning re-  
10 quired under section 740.10 of title 21,  
11 Code of Federal Regulations (or any suc-  
12 cessor regulations). The responsible person  
13 shall maintain records documenting any  
14 such substantiation of safety and the infor-  
15 mation on which such determination is  
16 based until 5 years after the finished prod-  
17 uct is no longer marketed, except that a  
18 responsible person for a domestic company  
19 whose sales are under \$2,000,000 per year  
20 shall maintain such records for at least 2  
21 years after the finished product is no  
22 longer marketed.

23 “(B) SMALL BUSINESSES.—

24 “(i) REQUIREMENTS.—In the case of  
25 a registrant described in clause (ii), the

1 registration shall contain the following in-  
2 formation:

3 “(I) Each facility’s name and full  
4 address, identifying the precise phys-  
5 ical location of the facility.

6 “(II) The name, title, street ad-  
7 dress, telephone number, and elec-  
8 tronic contact information of the  
9 emergency contact for the facility.

10 “(III) The consumer product cat-  
11 egory or categories of each cosmetic  
12 product or cosmetic formulation man-  
13 ufactured, processed, packed, or held  
14 at the facility or on whose label the  
15 facility’s name and address appear.

16 “(ii) SMALL BUSINESS REG-  
17 ISTRANTS.—A registrant described in this  
18 clause is a domestic registrant—

19 “(I) whose average gross annual  
20 sales in the United States of cosmetic  
21 products for the previous 3-year pe-  
22 riod is between \$500,000 and  
23 \$2,000,000 (or between \$1,000,000  
24 and \$2,000,000 in the case of sales of

1 cosmetic products produced in a pri-  
2 vate residence); and

3 “(II) who does not produce—

4 “(aa) products that are in-  
5 tended to go on the eye area;

6 “(bb) lip products with  
7 color;

8 “(cc) products that are in-  
9 jected;

10 “(dd) products that are in-  
11 tended for internal use; or

12 “(ee) products that are  
13 meant to alter appearance for  
14 more than 24 hours.

15 “(iii) GUIDANCE.—The Food and  
16 Drug Administration shall, after consulta-  
17 tion with the Small Business Administra-  
18 tion and small businesses that manufac-  
19 ture cosmetics, provide additional guidance  
20 for small businesses on compliance with  
21 the requirements of this section that would  
22 apply to small business registrants. Such  
23 guidance shall include specific examples of  
24 options for compliance that do not place an  
25 undue burden on small businesses.

1           “(3) ABBREVIATED REGISTRATION.—The Food  
2           and Drug Administration shall provide for an abbrevi-  
3           ated registration renewal process for any registrant  
4           that has not had any changes to the required infor-  
5           mation with respect to the facility or facilities in-  
6           volved since the registrant submitted the preceding  
7           registration.

8           “(f) COSMETIC PRODUCT INGREDIENT LISTING.—

9           “(1) IN GENERAL.—The ingredient listing re-  
10          quired pursuant to subsection (e)(2)(A)(xi) shall in-  
11          clude—

12                   “(A) the unique identifier assigned under  
13                   section (h), as applicable, of—

14                           “(i) each facility where the cosmetic  
15                           product is manufactured or processed; and

16                                   “(ii) the facility whose name and ad-  
17                                   dress appear on the label, unless the state-  
18                                   ment is filed by a contract manufacturer  
19                                   described in section 604(6)(B);

20                           “(B) the brand name and the full name for  
21                           the cosmetic product as it appears on the label;

22                                   “(C) the cosmetic product listing number,  
23                                   if any, previously assigned to the cosmetic prod-  
24                                   uct by the Food and Drug Administration  
25                                   under paragraph (4);

1           “(D) the applicable cosmetic category for  
2 the cosmetic product;

3           “(E) a list of ingredients in the cosmetic  
4 product, including a range of possible amounts  
5 of each ingredient, identified by the name  
6 adopted in regulations promulgated by the Food  
7 and Drug Administration, if any, or by the  
8 common or usual name of the ingredient, which  
9 shall include—

10                   “(i) a list of fragrances, flavors, and  
11 colors that may be included in the product,  
12 interchangeably, with ranges of possible  
13 amounts, which shall include—

14                           “(I) in the case of fragrances  
15 that are purchased from a fragrance  
16 supplier, identification of the fra-  
17 grances by the name or code provided  
18 by the supplier, including the name  
19 and contact information for the fra-  
20 grance supplier; and

21                           “(II) in the case of flavors that  
22 are purchased from a flavor supplier,  
23 identification of the flavors by the  
24 name or code provided by the sup-  
25 plier, including the name and contact

1 information for the flavor supplier;

2 and

3 “(ii) other appropriate interchange-

4 able ingredients as the Food and Drug Ad-

5 ministration may specify in regulations or

6 guidance that may be included in the prod-

7 uct, with ranges of possible amounts;

8 “(F) the title and full contact information

9 of each individual submitting the statement;

10 “(G) if applicable, information on the la-

11 beling required under section 612; and

12 “(H) if applicable, information showing

13 that the cosmetic ingredient or ingredients in

14 the product meet any specified conditions of use

15 or tolerances required following a final deter-

16 mination of safety under section 607(d).

17 “(2) ADDITIONAL INFORMATION.—In the case

18 of a cosmetic ingredient statement that includes a

19 list of fragrances or flavors that are purchased from

20 a fragrance or flavor supplier as described in para-

21 graph (1)(E)(i), upon request by the Food and Drug

22 Administration, the fragrance or flavor supplier shall

23 submit to the Food and Drug Administration the

24 complete list of ingredients in specific fragrances or

1 flavors, not later than 30 days after receiving such  
2 request.

3 “(3) COSMETIC PRODUCT INGREDIENT STATE-  
4 MENT FOR NEW OR REFORMULATED COSMETIC  
5 PRODUCTS.—

6 “(A) IN GENERAL.—Except as provided  
7 under subparagraph (B), in the case of a cos-  
8 metic product that is first marketed after the  
9 date of enactment of the Personal Care Prod-  
10 ucts Safety Act or a cosmetic product that is  
11 reformulated after such date of enactment, the  
12 responsible person shall submit a cosmetic in-  
13 gredient statement to the Food and Drug Ad-  
14 ministration within 60 days of first marketing  
15 the new cosmetic product or reformulated cos-  
16 metic product, and annually thereafter.

17 “(B) SMALL BUSINESSES.—The Food and  
18 Drug Administration shall allow a responsible  
19 person that is a business that meets the appli-  
20 cable industry-based small business size stand-  
21 ard established by the Administrator of the  
22 Small Business Administration under section 3  
23 of the Small Business Act to have a period  
24 longer than 60 days to submit an initial new



1 cosmetic ingredient statement under subpara-  
2 graph (A).

3 “(C) DEFINITION.—A cosmetic product  
4 shall not be considered first marketed or refor-  
5 mulated after the date of enactment under sub-  
6 paragraph (A) if the only change in such prod-  
7 uct is in—

8 “(i) the amount of an existing ingre-  
9 dient if it is within the range previously re-  
10 ported under paragraph (1)(E); or

11 “(ii) the addition or subtraction of a  
12 fragrance, flavor, or color, or such other  
13 interchangeable ingredients specified by  
14 the Food and Drug Administration in reg-  
15 ulations or guidance, previously reported  
16 as a potential ingredient under paragraph  
17 (1)(E), if, in the case of such an addition,  
18 the amount is within the range previously  
19 reported.

20 “(4) COSMETIC PRODUCTS LIST.—At the time  
21 of the initial submission of any cosmetic ingredient  
22 statement under this section, the Food and Drug  
23 Administration shall assign a unique cosmetic prod-  
24 uct listing number to the cosmetic ingredient state-  
25 ment. Based on such cosmetic ingredient statements,

1 the Food and Drug Administration shall compile  
2 and maintain a list of cosmetic products distributed  
3 in the United States, including the ingredients of  
4 each such product, and shall make available such list  
5 to any State, upon request. Information disclosed to  
6 a State that is exempt from disclosure under section  
7 552(b)(4) of title 5, United States Code, shall be  
8 treated as a trade secret and confidential informa-  
9 tion by the State.

10 “(g) INCOMPLETE OR INACCURATE REGISTRA-  
11 TION.—

12 “(1) IN GENERAL.—Not earlier than 10 days  
13 after providing notice of the intent to cancel a reg-  
14 istration and the basis for such cancellation, the  
15 Food and Drug Administration may cancel a reg-  
16 istration under this section if the Food and Drug  
17 Administration has reasonable grounds to believe  
18 that the registration was not properly completed or  
19 updated in accordance with this section or otherwise  
20 contains false, incomplete, or inaccurate information.

21 “(2) TIMELY UPDATE OR CORRECTION.—If, not  
22 later than 7 days after receipt of a notice of intent  
23 to cancel, the responsible person corrects the reg-  
24 istration in accordance with the basis for the can-  
25 cellation, and the required registration fee, if any, is

1       paid, the Food and Drug Administration shall not  
2       cancel such registration.

3       “(h) UNIQUE IDENTIFIER.—At the time of the initial  
4 registration of any cosmetic facility under this section, the  
5 Food and Drug Administration shall assign a unique iden-  
6 tifier to the facility.

7       “(i) REGISTRY OF FACILITIES.—

8               “(1) IN GENERAL.—The Food and Drug Ad-  
9 ministration shall compile, maintain, and update a  
10 registry of facilities that are registered under this  
11 section, and shall remove from such registry the  
12 name of any facility whose registration under this  
13 section is cancelled. The registry shall be publicly  
14 available.

15               “(2) PUBLIC AVAILABILITY EXCEPTIONS.—In-  
16 formation derived from the registry or registration  
17 documents that discloses the residential address of a  
18 registrant or that discloses specific facilities where  
19 specific cosmetic products are manufactured or proc-  
20 essed shall not be subject to disclosure under section  
21 552 of title 5, United States Code.

22 **“SEC. 606. SUSPENSION OF REGISTRATION OR COSMETIC**  
23 **INGREDIENT STATEMENT.**

24       “(a) SUSPENSION OF REGISTRATION OF A FACIL-  
25 ITY.—If the Food and Drug Administration determines

1 that a cosmetic formulation or cosmetic product manufac-  
2 tured or processed by a registered facility and distributed  
3 in the United States has a reasonable probability of caus-  
4 ing serious adverse health consequences or death to hu-  
5 mans, and the Food and Drug Administration has a rea-  
6 sonable belief that other products manufactured or proc-  
7 essed by the facility may be similarly affected because of  
8 a failure that cannot be isolated to a single product or  
9 products or is sufficiently pervasive to raise concerns  
10 about other products manufactured in the facility, the  
11 Food and Drug Administration may suspend the registra-  
12 tion of a facility.

13 “(b) SUSPENSION OF COSMETIC INGREDIENT STATE-  
14 MENT.—If the Food and Drug Administration determines  
15 that a cosmetic product manufactured in a registered fa-  
16 cility has a reasonable probability of causing serious ad-  
17 verse health consequences or death to humans, the Food  
18 and Drug Administration may suspend the cosmetic ingre-  
19 dient statement of that product.

20 “(c) NOTICE OF SUSPENSION.—Before suspending a  
21 facility registration or a cosmetic ingredient statement  
22 under this section, the Food and Drug Administration  
23 shall provide—

24 “(1) notice to the facility registrant of the cos-  
25 metic product or formulation or other responsible

1 person, as appropriate, of the intent to suspend the  
2 facility registration or the cosmetic ingredient state-  
3 ment, which shall specify the basis of the determina-  
4 tion by the Food and Drug Administration that the  
5 facility or the cosmetic ingredient should be sus-  
6 pended and recommendations for specific actions to  
7 avoid suspension; and

8 “(2) an opportunity, within 2 business days of  
9 the notice provided under paragraph (1), for the re-  
10 sponsible person to address the reasons for possible  
11 suspension of the facility registration or cosmetic in-  
12 gredient statement.

13 “(d) REINSTATEMENT.—Upon a determination by  
14 the Food and Drug Administration that adequate grounds  
15 do not exist to continue the suspension actions, the Food  
16 and Drug Administration shall promptly vacate the sus-  
17 pension and reinstate the registration of the facility or the  
18 cosmetic ingredient statement.

19 “(e) EFFECT OF SUSPENSION.—

20 “(1) REGISTRATION.—If the registration of a  
21 facility is suspended under this section, no person  
22 shall introduce or deliver for introduction into inter-  
23 state commerce cosmetics or cosmetic products from  
24 such facility.

1           “(2) COSMETIC INGREDIENT STATEMENT.—If  
2           the cosmetic ingredient statement for a cosmetic  
3           product is suspended under this section, no person  
4           shall introduce or deliver for introduction into inter-  
5           state commerce any cosmetic product that is the  
6           subject of such statement.

7           “(f) NO DELEGATION.—The authority conferred by  
8           this section to issue an order to suspend a registration  
9           or vacate an order of suspension shall not be delegated  
10          to any officer or employee other than the Commissioner.”.

11   **SEC. 102. REVIEW OF INGREDIENTS AND NON-FUNCTIONAL**  
12                           **CONSTITUENTS.**

13          (a) AMENDMENTS.—Chapter VI of the Federal Food,  
14          Drug, and Cosmetic Act (21 U.S.C. 361 et seq.), as  
15          amended by section 101, is further amended by adding  
16          at the end the following:

17   **“SEC. 607. REVIEW OF INGREDIENTS AND NON-FUNC-**  
18                           **TIONAL CONSTITUENTS.**

19          “(a) INGREDIENTS AND NON-FUNCTIONAL CON-  
20          STITUENTS SUBJECT TO REVIEW.—

21               “(1) IN GENERAL.—The Food and Drug Ad-  
22               ministration shall review the safety of the cosmetic  
23               ingredients and non-functional constituents listed  
24               under paragraph (3), as modified under subsection  
25               (c), if applicable, and issue an order under sub-

1 section (d) with respect to the use of each such in-  
2 ingredient and presence of each such non-functional  
3 constituent.

4 “(2) PUBLIC NOTICE AND COMMENT.—At the  
5 initiation of the review of each cosmetic ingredient  
6 or non-functional constituent, the Food and Drug  
7 Administration shall open a docket for the submis-  
8 sion of public comment and additional data relevant  
9 to the safety of the ingredient or non-functional con-  
10 stituent. The Food and Drug Administration shall  
11 provide 60 days for public comment.

12 “(3) COSMETIC INGREDIENTS.—

13 “(A) IN GENERAL.—Beginning in fiscal  
14 year 2022, the Food and Drug Administration  
15 shall annually select and complete a safety re-  
16 view of at least 5 cosmetic ingredients or non-  
17 functional constituents that were not reviewed  
18 in the prior 3 years, from a list determined in  
19 consultation with the cosmetic industry and  
20 consumer and health groups. The Food and  
21 Drug Administration may combine selected cos-  
22 metics ingredients or non-functional constitu-  
23 ents into categories for purposes of such review.  
24 The Food and Drug Administration may modify  
25 such list under subsection (c).

1           “(B) CONSIDERATIONS.—The determina-  
2           tion of which ingredients or functional ingredi-  
3           ents will be reviewed in a given year shall be  
4           publicized in annual reports to Congress and  
5           the public, in accordance with section 617. The  
6           review of any cosmetic ingredient or non-func-  
7           tional constituent shall commence with a public  
8           announcement by the Food and Drug Adminis-  
9           tration and the opening of a docket as required  
10          under paragraph (2).

11          “(4) COMMENT PERIOD.—As part of the annual  
12          reporting to Congress and the public under section  
13          617, the Food and Drug Administration shall solicit  
14          public comment on which cosmetic ingredients or  
15          non-functional constituents on the list are of great-  
16          est interest to be reviewed next for early review and  
17          which additional cosmetic ingredients or non-func-  
18          tional constituents should be added to the list. The  
19          public may submit comments to the Food and Drug  
20          Administration at any time during the year regard-  
21          ing which cosmetic ingredients or non-functional  
22          constituents of interest the Food and Drug Adminis-  
23          tration may consider during that year or subsequent  
24          years.



1       “(b) LIST.—The Food and Drug Administration  
2 shall maintain a list, posted on the Internet website of the  
3 Food and Drug Administration, of the cosmetic ingredi-  
4 ents and non-functional constituents for which final orders  
5 have been issued under subsection (d)(3), the finding  
6 made for each such ingredient or non-functional con-  
7 stituent under subsection (d)(4), as modified by any order  
8 under subsection (f), if applicable, and, if applicable, com-  
9 pliance dates that are the subject of a final order under  
10 subsection (e).

11       “(c) INITIATIVE OF THE FDA.—The Food and Drug  
12 Administration may at any time propose the issuance of  
13 an order on the safety of a cosmetic ingredient or non-  
14 functional constituent that was not previously listed in  
15 subsection (a) or under section 617(a)(3). The Food and  
16 Drug Administration shall follow the same procedures and  
17 policies for review of any cosmetic ingredient or non-func-  
18 tional constituent so proposed as for the ingredients and  
19 constituents reviewed pursuant to subsection (a).

20       “(d) DETERMINATION ON SAFETY.—

21               “(1) INITIAL PROPOSED ADMINISTRATIVE  
22 ORDER.—Following consideration of data and com-  
23 ments to the public docket and any other informa-  
24 tion before the Food and Drug Administration, the  
25 Food and Drug Administration shall determine

1       whether there is adequate evidence to make an ini-  
2       tial finding on the safety of the ingredient or non-  
3       functional constituent. If the Food and Drug Ad-  
4       ministration determines that there is adequate evi-  
5       dence, the Food and Drug Administration shall issue  
6       a proposed administrative order and shall post such  
7       order on the Internet website of the Food and Drug  
8       Administration, notwithstanding subchapter II of  
9       chapter 5 of title 5, United States Code.

10           “(2) PUBLIC COMMENT.—Upon publication of  
11       the proposed administrative order described in para-  
12       graph (1), the Food and Drug Administration shall  
13       open a docket for the submission of public comment.  
14       The Food and Drug Administration shall provide 30  
15       days for public comment following publication of the  
16       proposed administrative order.

17           “(3) FINAL ADMINISTRATIVE ORDER.—Fol-  
18       lowing the public comment period described in para-  
19       graph (2) and consideration of comments to the pub-  
20       lic docket and any other information before the Food  
21       and Drug Administration, the Food and Drug Ad-  
22       ministration shall determine whether there is ade-  
23       quate evidence to make a final finding on the safety  
24       of the ingredient or non-functional constituent. If  
25       the Food and Drug Administration determines that

1       there is adequate evidence, the Food and Drug Ad-  
2       ministration shall issue a final administrative order  
3       and shall post such order on the Internet website of  
4       the Food and Drug Administration, notwithstanding  
5       subchapter II of chapter 5 of title 5, United States  
6       Code.

7               “(4) DETERMINATIONS.—In the proposed ad-  
8       ministrative order or the final administrative order,  
9       as applicable, the Food and Drug Administration  
10      shall make a determination that the ingredient or  
11      non-functional constituent is—

12                   “(A) safe in cosmetic products under speci-  
13                   fied conditions of use or tolerances;

14                   “(B) safe in cosmetic products without the  
15                   need for specified conditions of use or toler-  
16                   ances; or

17                   “(C) not safe in cosmetic products.

18               “(5) CONDITIONS OF USE AND TOLERANCES.—  
19      An order under paragraph (4)(A) shall include such  
20      conditions on the use of an ingredient or such toler-  
21      ances on the presence of a non-functional con-  
22      stituent as are necessary for the safety of cosmetic  
23      products containing such ingredient or non-func-  
24      tional constituent, including—

1           “(A) limits on the amount or concentration  
2 of the ingredient or non-functional constituent  
3 that may be present in a cosmetic product, in-  
4 cluding limits in products intended for children  
5 and other vulnerable populations, and limits on  
6 use near the eye or mucosal membranes;

7           “(B) warnings that are necessary or appro-  
8 priate under section 612, including warnings re-  
9 lated to use by children, pregnant women, popu-  
10 lations with high exposure to the ingredient  
11 (such as workers who are exposed through pro-  
12 duction practices or handling of final products),  
13 or other vulnerable populations, to help ensure  
14 safe use of cosmetic products containing the in-  
15 gredient or non-functional constituent; and

16           “(C) such other screening, safety protocol,  
17 or other similar conditions as are necessary for  
18 the safety of cosmetic products containing such  
19 ingredient or non-functional constituent.

20           “(6) PUBLIC NOTICE.—A final order under this  
21 subsection shall set forth the determination of the  
22 Food and Drug Administration on safety, any condi-  
23 tions of use or tolerances under subparagraph (A) or  
24 (B) of paragraph (4) and a summary of the valid  
25 scientific evidence supporting the finding. The order

1 shall be effective upon its publication on the Internet  
2 website of the Food and Drug Administration and  
3 shall be considered final agency action.

4 “(e) ORDER.—

5 “(1) IN GENERAL.—If the Food and Drug Ad-  
6 ministration issues a final administrative order  
7 under subparagraph (A) or (C) of subsection (d)(4),  
8 the Food and Drug Administration shall, at the  
9 same time as publication of the notice under sub-  
10 section (d)(6), publish a proposed order identifying  
11 dates by which use of the ingredient or non-func-  
12 tional constituent in cosmetic products shall comply  
13 with the final administrative order, and provide 60  
14 days for public comment, including comment on  
15 whether compliance is feasible within the proposed  
16 dates. After considering comments on the proposed  
17 order, the Food and Drug Administration shall pub-  
18 lish in the Federal Register a final order.

19 “(2) CONTENT.—The public notice information  
20 regarding the final order under paragraph (1) shall  
21 include a summary that is written in plain and un-  
22 derstandable language that is comprehensible and  
23 meaningful for consumers. The summary shall in-  
24 clude information on any conditions of use or warn-  
25 ings required under section 612, including the appli-

1 cation to vulnerable populations, the types of safety  
2 studies evaluated, and any additional relevant infor-  
3 mation that was part of the review process.

4 “(f) MODIFICATION OF AN ORDER.—An order issued  
5 under subsection (d) or (e) may be modified or revoked  
6 by the Food and Drug Administration on the initiative of  
7 the Food and Drug Administration or in response to a  
8 petition.

9 “(g) INADEQUATE EVIDENCE.—

10 “(1) NOTICE; EXTENSION.—If the Food and  
11 Drug Administration determines that the available  
12 data and information are not adequate to make a  
13 proposed or final determination regarding safety  
14 under subsection (d)(4), with respect to a cosmetic  
15 ingredient or non-functional constituent, the Food  
16 and Drug Administration shall—

17 “(A) publish such finding on the Internet  
18 website of the Food and Drug Administration  
19 not later than 90 days after the close of the rel-  
20 evant comment period for the ingredient or  
21 non-functional constituent under subsection  
22 (a)(2), in the case of a proposed order, or sub-  
23 section (d)(2), in the case of a final order; and

24 “(B)(i) include a notice providing inter-  
25 ested persons an additional 30 days from the

1 notice date to provide additional data and infor-  
2 mation; and

3 “(ii) if, after the 30-day period under  
4 clause (i), the Food and Drug Administration  
5 determines that additional safety substantiation  
6 with respect to such ingredient or non-func-  
7 tional constituent is necessary to make a safety  
8 determination—

9 “(I) include a notice specifying an ad-  
10 ditional time period, not to exceed 18  
11 months from the notice date, during which  
12 time the assurance made by a responsible  
13 person under section 605(e)(2)(A)(xii) with  
14 respect to the safety of such cosmetic in-  
15 gredient or non-functional constituent shall  
16 be deemed to be in compliance with the re-  
17 quirements of this Act, but shall not affect  
18 final determinations of safety under sub-  
19 section (d); and

20 “(II) plan to obtain such data and in-  
21 formation.

22 “(2) DETERMINATION; ORDER.—

23 “(A) INADEQUATE DATA AND INFORMA-  
24 TION.—If the Food and Drug Administration  
25 determines, after considering any additional

1 data and information submitted under para-  
2 graph (1)(B), that the available data and infor-  
3 mation still are not adequate to make a deter-  
4 mination regarding safety under subsection  
5 (d)(4), the Food and Drug Administration  
6 shall, within 90 days of the close of the addi-  
7 tional time period provided under paragraph  
8 (1)(B), issue a proposed order or a final admin-  
9 istrative order—

10 “(i) making a determination that the  
11 ingredient or non-functional constituent  
12 has not been shown to be safe in cosmetic  
13 products; and

14 “(ii) explaining why the available data  
15 and information are not adequate to assess  
16 the safety of the ingredient or non-func-  
17 tional constituent.

18 “(B) ADEQUATE DATA AND INFORMA-  
19 TION.—If the Food and Drug Administration  
20 determines, after considering any additional  
21 data and information submitted under para-  
22 graph (1)(B), that the available data and infor-  
23 mation are adequate to make a determination  
24 regarding safety under subsection (d)(4), the  
25 Food and Drug Administration shall, within



1           180 days of the close of the comment period,  
2           issue a proposed order, followed by a final  
3           order, on such cosmetic ingredient or non-func-  
4           tional constituent, in accordance with such sub-  
5           section.

6           “(h) SAFETY ASSESSMENT.—

7           “(1) IN GENERAL.—In assessing the safety of  
8           an ingredient or non-functional constituent, the  
9           Food and Drug Administration shall consider wheth-  
10          er there is adequate evidence to support a reasonable  
11          certainty among competent scientists that the ingre-  
12          dient is not harmful under the recommended or sug-  
13          gested conditions of use or customary or usual use,  
14          or that a non-functional constituent is not harmful  
15          under the recommended or suggested tolerance levels  
16          or the level at which it is customarily or usually  
17          present. The Food and Drug Administration may  
18          not consider an ingredient or non-functional con-  
19          stituent harmful solely because it can cause minor  
20          adverse health reactions, such as minor transient al-  
21          lergic reactions or minor transient skin irritations,  
22          in some users.

23          “(2) FACTORS.—In assessing the safety of an  
24          ingredient or non-functional constituent, the Food

1 and Drug Administration shall consider, among  
2 other relevant factors, the following:

3 “(A) The probable human exposure to the  
4 ingredient or non-functional constituent from  
5 expected use in cosmetics.

6 “(B) The probable cumulative and aggregate  
7 effect in humans of relevant exposure to  
8 the ingredient or non-functional constituent or  
9 to any chemically or pharmacologically related  
10 substances from use in cosmetics or other prod-  
11 ucts with similar routes of exposure under rec-  
12 ommended or suggested conditions of use or  
13 their customary use, to the extent adequate  
14 data is available for analysis. In appropriate  
15 cases, the Food and Drug Administration may  
16 consider available information on the total expo-  
17 sure to an ingredient or non-functional con-  
18 stituent from all sources.

19 “(C) Whether warnings or recommenda-  
20 tions in a product label required under section  
21 612, as part of any conditions of use or toler-  
22 ances imposed by the Food and Drug Adminis-  
23 tration, would be necessary and appropriate to  
24 help ensure the safety of the ingredient or non-  
25 functional constituent.

1 “(3) DATA AND INFORMATION.—

2 “(A) REQUIRED INFORMATION.—A deter-  
3 mination that an ingredient or non-functional  
4 constituent is safe in cosmetics shall be based  
5 upon adequate evidence submitted or otherwise  
6 known to the Food and Drug Administration,  
7 which shall include full reports of all available  
8 studies, published or unpublished, that are ade-  
9 quately designed to show whether the ingredient  
10 or non-functional constituent is safe. Such stud-  
11 ies may include in vitro and in silico studies  
12 and epidemiological studies, biomonitoring stud-  
13 ies, and studies focused on various points dur-  
14 ing the lifespan of the subject, that use scientifi-  
15 cally valid methodology.

16 “(B) ADDITIONAL RELEVANT INFORMA-  
17 TION.—The Food and Drug Administration  
18 shall consider any other relevant information  
19 related to the safety of the ingredient or non-  
20 functional constituent, including—

21 “(i) adverse event reports;

22 “(ii) findings and information from  
23 State, Federal, national, and international  
24 entities and other bodies composed of sci-  
25 entific and medical experts;

1                   “(iii) if the ingredient or non-func-  
2                   tional constituent is lawfully used or  
3                   present in other products regulated by the  
4                   Food and Drug Administration, the sci-  
5                   entific basis for such use; and

6                   “(iv) experience with the ingredient or  
7                   non-functional constituent in products that  
8                   are distributed in the United States or in  
9                   other countries, if such experience is well-  
10                  documented and has resulted in substantial  
11                  human exposure to the ingredient or non-  
12                  functional constituent over time.

13               “(i) COAL-TAR HAIR DYE.—Coal-tar hair dye shall  
14               be subject to the conditions of section 601(a) unless the  
15               Food and Drug Administration has issued a final deter-  
16               mination for a coal-tar hair dye ingredient under sub-  
17               section (d)(4)(C).

18               “(j) CERTAIN INGREDIENTS IMPARTING PIGMENT.—  
19               Ingredients imparting pigment to cosmetic products that  
20               are subject to review and approval pursuant to section  
21               721(b) shall not be subject to review under this section.”.

22               (b) GAO REPORT.—The Comptroller General of the  
23               United States shall conduct a review of the program of  
24               review of cosmetic ingredients and non-functional con-  
25               stituents under section 607 of the Federal Food, Drug,

1 and Cosmetic Act, as added by subsection (a), and, not  
2 later than 5 years after the date of enactment of this Act,  
3 issue a report on such review.

4 **SEC. 103. GOOD MANUFACTURING PRACTICES FOR COS-**  
5 **METICS.**

6 (a) IN GENERAL.—Chapter VI of the Federal Food,  
7 Drug, and Cosmetic Act (21 U.S.C. 361 et seq.), as  
8 amended by section 102, is further amended by adding  
9 at the end the following:

10 **“SEC. 608. GOOD MANUFACTURING PRACTICES FOR COS-**  
11 **METICS.**

12 “(a) IN GENERAL.—The Food and Drug Administra-  
13 tion shall review national and international standards for  
14 cosmetic good manufacturing practices that are in exist-  
15 ence on the date of enactment of the Personal Care Prod-  
16 ucts Safety Act and shall develop and implement, through  
17 regulations, standards consistent, to the extent the Food  
18 and Drug Administration determines practicable and ap-  
19 propriate, with such national and international standards  
20 for cosmetic good manufacturing practices to ensure that  
21 requirements of this chapter with respect to the manufac-  
22 ture of cosmetic products are in harmony.

23 “(b) CONSULTATION.—The standards under sub-  
24 section (a) shall include simplified good manufacturing  
25 practices for small businesses that take into account the

1 size and scope of the business, developed in consultation  
2 with the Small Business Administration.

3 “(c) TIMEFRAME.—The Food and Drug Administra-  
4 tion shall publish a proposed rule described in subsection  
5 (a) not later than 18 months after the date of enactment  
6 of the Personal Care Products Safety Act and shall pub-  
7 lish a final such rule not later than 3 years after such  
8 date of enactment.”.

9 (b) EFFECTIVE DATE FOR COSMETIC MANUFACTUR-  
10 ERS.—

11 (1) LARGE BUSINESSES.—For businesses of a  
12 size greater than the Small Business Administra-  
13 tion’s standard for a small business, section 608 of  
14 the Federal Food, Drug, and Cosmetic Act (as  
15 added by subsection (a)) shall take effect beginning  
16 180 days after the date on which the Food and  
17 Drug Administration makes effective cosmetic good  
18 manufacturing practices.

19 (2) SMALL BUSINESSES.—For businesses of a  
20 size that meets the Small Business Administration’s  
21 standard for a small business, section 608 of the  
22 Federal Food, Drug, and Cosmetic Act (as added by  
23 subsection (a)) shall take effect beginning 2 years  
24 after the date the Food and Drug Administration

1 makes effective cosmetic good manufacturing prac-  
2 tices.

3 **SEC. 104. ADVERSE EVENT REPORTS.**

4 Chapter VI of the Federal Food, Drug, and Cosmetic  
5 Act (21 U.S.C. 361 et seq.), as amended by section  
6 103(a), is further amended by adding at the end the fol-  
7 lowing:

8 **“SEC. 609. ADVERSE EVENT REPORTING FOR COSMETICS.**

9 “(a) IN GENERAL.—With respect to any cosmetic  
10 product distributed in the United States, the responsible  
11 person shall submit to the Food and Drug Administration  
12 a report of any serious adverse event associated with such  
13 cosmetic product, when used in the United States, accom-  
14 panied by a copy of the label on or with the retail pack-  
15 aging of the cosmetic, any new medical information, re-  
16 lated to a submitted serious adverse event report that is  
17 received by the responsible person, and an annual report  
18 for all adverse events received by the responsible person.

19 “(b) DEFINITIONS.—In this section:

20 “(1) An ‘adverse event’ for a cosmetic product  
21 is a health-related event associated with the use of  
22 this product that is adverse.

23 “(2) A ‘serious adverse event’ for a cosmetic  
24 product is an adverse event that—

25 “(A) results in—

1 “(i) death;

2 “(ii) a life-threatening experience;

3 “(iii) inpatient hospitalization;

4 “(iv) a persistent or significant dis-  
5 ability or incapacity;

6 “(v) congenital anomaly or birth de-  
7 fect; or

8 “(vi) significant disfigurement, includ-  
9 ing serious and persistent rashes or infec-  
10 tions and significant hair loss; or

11 “(B) requires, based on appropriate med-  
12 ical judgment, a medical or surgical interven-  
13 tion to prevent an outcome described in sub-  
14 paragraph (A).

15 “(c) SUBMISSION OF REPORTS.—

16 “(1) SERIOUS ADVERSE EVENT REPORTS.—Ex-  
17 cept as provided in paragraph (2), with respect to a  
18 cosmetic product distributed in the United States,  
19 the responsible person shall submit a serious adverse  
20 event report to the Food and Drug Administration  
21 not later than 15 business days after information  
22 concerning the adverse event is received. If a serious  
23 adverse event report for a cosmetic with drug prop-  
24 erties is filed using Form FDA 3500A (or any suc-  
25 cessor form developed for such purpose) or its elec-



1       tronic equivalent for over-the-counter drugs, the re-  
2       sponsible person shall not have to submit a duplica-  
3       tive serious adverse event report under this section.

4           “(2) NEW MEDICAL INFORMATION.—The re-  
5       sponsible person shall submit to the Food and Drug  
6       Administration any new medical information, related  
7       to a submitted serious adverse event report that is  
8       received by the responsible person within 1 year of  
9       the initial report, and shall submit such information  
10      not later than 15 business days after the new infor-  
11     mation is received by the responsible person.

12          “(3) CONSOLIDATION OF REPORTS.—The Food  
13      and Drug Administration shall provide for systems  
14      to enable the responsible person to submit a single  
15      report that includes duplicate reports of, or new  
16      medical information related to, a serious adverse  
17      event.

18          “(4) ANNUAL REPORT.—

19           “(A) IN GENERAL.—Not later than March  
20      1 of each year, except as provided under sub-  
21      paragraph (C), the responsible person shall sub-  
22      mit an electronic report for the prior calendar  
23      year for each cosmetic product marketed during  
24      that year.

1           “(B) CONTENTS.—Each report under this  
2 paragraph shall contain a summary of all ad-  
3 verse events received during the reporting pe-  
4 riod, a complete list of individual reports, and  
5 an estimate of the total number of product  
6 units estimated to have been distributed to con-  
7 sumers in the United States during such period.  
8 The report shall not include consumer com-  
9 plaints that are solely regarding efficacy and do  
10 not contain any information about an adverse  
11 event. The Food and Drug Administration shall  
12 further specify the contents of the annual elec-  
13 tronic report by regulation or guidance.

14           “(C) SMALL BUSINESS EXCEPTION.—In  
15 the case of a domestic facility for which the av-  
16 erage gross annual sales in cosmetic products in  
17 the United States over the previous 3-year pe-  
18 riod is not more than \$2,000,000, the respon-  
19 sible person is not required to submit an annual  
20 report under this paragraph.

21           “(5) EXEMPTION.—The Food and Drug Ad-  
22 ministration may establish by regulation an exemp-  
23 tion to any of the requirements under this sub-  
24 section if the Food and Drug Administration deter-  
25 mines that such exemption is supported by adequate

1 evidence and would have no adverse effect on public  
2 health.

3 “(d) REQUIREMENTS.—

4 “(1) IN GENERAL.—Each serious adverse event  
5 report under this section shall be submitted to the  
6 Food and Drug Administration using an electronic  
7 system of the Food and Drug Administration. The  
8 Food and Drug Administration shall make such elec-  
9 tronic system available not later than 1 year after  
10 the date of enactment of the Personal Care Products  
11 Safety Act.

12 “(2) MODIFICATION.—The format of the re-  
13 porting system may be modified by the Food and  
14 Drug Administration and the reports may include  
15 additional information. The Food and Drug Admin-  
16 istration may, in guidance, further specify the for-  
17 mat and contents of required reports.

18 “(3) SCOPE OF SERIOUS ADVERSE EVENT RE-  
19 PORT.—A serious adverse event report (including all  
20 information submitted in the initial report or added  
21 later) submitted to the Food and Drug Administra-  
22 tion under subsection (a) includes—

23 “(A) a report under section 756 with re-  
24 spect to safety and related to a specific cos-  
25 metic product;

1           “(B) a record about an individual who suf-  
2           fered the serious adverse event under section  
3           552a of title 5, United States Code;

4           “(C) a medical or similar file documenting  
5           the serious adverse event, the disclosure of  
6           which would constitute a violation of section  
7           552(b)(6) of such title 5, and shall not be pub-  
8           licly disclosed unless all personally identifiable  
9           information is redacted; and

10           “(D) contact information for the individual  
11           reporting the serious adverse event.

12           “(4) RESPONSIBILITY TO GATHER INFORMA-  
13           TION.—After an individual initiates the reporting of  
14           a serious adverse event, the responsible person for  
15           the cosmetic product shall actively gather all of the  
16           information to complete and file the report with the  
17           Food and Drug Administration.

18           “(5) NO ADVERSE EVENTS TO REPORT.—The  
19           Food and Drug Administration shall provide an op-  
20           tion as part of the electronic registration process for  
21           the responsible person to indicate if such responsible  
22           person had no adverse events to report over the pre-  
23           vious year. With respect to a responsible person who  
24           received no adverse event reports for a year, the an-  
25           nual adverse event report requirement may be met

1 by indicating no such events on the annual registra-  
2 tion form.

3 “(e) LIMITATION WITH RESPECT TO ADVERSE  
4 EVENT REPORTS.—The submission of an adverse event  
5 report in compliance with subsection (a) shall not con-  
6 stitute an admission that the cosmetic involved caused or  
7 contributed to the adverse event.

8 “(f) CONTACT INFORMATION.—The label of a cos-  
9 metic shall bear the domestic telephone number or elec-  
10 tronic contact information, and it is encouraged that the  
11 label include both the telephone number and electronic  
12 contact information, through which the responsible person  
13 may receive a report of an adverse event.

14 “(g) MAINTENANCE OF RECORDS.—The responsible  
15 person shall maintain records related to each report of an  
16 adverse event received by the responsible person for a pe-  
17 riod of 6 years.

18 “(h) AVAILABILITY TO STATES.—The Food and  
19 Drug Administration shall make available records sub-  
20 mitted under this section to any State, upon request. In-  
21 formation disclosed to a State that is exempt from dislo-  
22 sure under section 552(b)(4) of title 5, United States  
23 Code, shall be treated as a trade secret and confidential  
24 information by the State.

1       “(i) EFFECTIVE DATE OF REQUIREMENT WITH RE-  
2 SPECT TO SERIOUS ADVERSE EVENTS.—The requirement  
3 under this section to report serious adverse events shall  
4 become effective on the date that the Food and Drug Ad-  
5 ministration publicizes the availability of the electronic  
6 system described in subsection (d)(1).”.

7 **SEC. 105. RECORDS INSPECTION; MANDATORY RECALL AU-**  
8 **THORITY.**

9       Chapter VI of the Federal Food, Drug, and Cosmetic  
10 Act (21 U.S.C. 361 et seq.), as amended by section 104,  
11 is further amended by adding at the end the following:

12 **“SEC. 610. INSPECTION OF COSMETIC RECORDS.**

13       “(a) INSPECTION OF RECORDS.—Each manufacturer  
14 or processor of a cosmetic shall, at the request of an offi-  
15 cer or employee duly designated by the Food and Drug  
16 Administration, permit such officer or employee, upon  
17 presentation of appropriate credentials and written notice  
18 to such person, at reasonable times and within reasonable  
19 limits and in a reasonable manner, to have access to and  
20 copy—

21               “(1) all records maintained under section  
22 605(e)(2)(A)(xii) or 609 and in accordance with the  
23 rules promulgated by the Food and Drug Adminis-  
24 tration under section 608, as applicable; and

1           “(2) except as provided in subsection (b), all  
2 other records, if the Food and Drug Administra-  
3 tion—

4           “(A) has a reasonable belief that the cos-  
5           metic—

6           “(i) is adulterated;

7           “(ii) has caused a reportable serious  
8 adverse event; or

9           “(iii) contains an ingredient that sub-  
10           stantial new scientific information shows  
11           may be unsafe when present in a cosmetic;  
12           and

13           “(B) provides written notice of the basis  
14           for the Food and Drug Administration’s rea-  
15           sonable belief described in subparagraph (A).

16           “(b) EXCLUSIONS.—No inspection authorized by this  
17 section shall extend to financial data, pricing data, per-  
18 sonnel data (other than data as to qualification of tech-  
19 nical and professional personnel performing functions sub-  
20 ject to this Act), research data (other than safety data),  
21 or sales data other than shipment data.

22           “(c) SCOPE.—The requirements under subsection (a)  
23 apply to records maintained by or on behalf of such person  
24 in any format (including paper and electronic formats)  
25 and at any location.

1           “(d) PROTECTION OF SENSITIVE INFORMATION.—  
2 The Food and Drug Administration shall take appropriate  
3 measures to ensure that there are effective procedures to  
4 prevent the unauthorized disclosure of any trade secret or  
5 confidential information that is obtained by the Food and  
6 Drug Administration pursuant to this section. Information  
7 disclosed to a State that is exempt from disclosure under  
8 section 552(b)(4) of title 5, United States Code, shall be  
9 treated as a trade secret and confidential information by  
10 the State.

11           “(e) LIMITATIONS.—This section shall not be con-  
12 strued—

13                   “(1) to limit the authority of the Food and  
14 Drug Administration to inspect records or to require  
15 establishment and maintenance of records under any  
16 other provision of this Act; or

17                   “(2) to have any legal effect on section 552 of  
18 title 5, United States Code, or section 1905 of title  
19 18, United States Code.

20           “(f) SUBMISSION OF RECORDS.—

21                   “(1) IN GENERAL.—Any records required to be  
22 maintained by a responsible person under section  
23 605(e)(2)(A)(xii) shall, upon the written request of  
24 the Food and Drug Administration to the respon-  
25 sible person, be provided to the Food and Drug Ad-



1       ministration within a reasonable timeframe not to  
2       exceed 60 days, in either electronic or paper form.

3           “(2) CRITERIA.—The Food and Drug Adminis-  
4       tration may require records under paragraph (1)  
5       if—

6           “(A) the Food and Drug Administration  
7       has a reasonable belief, described in written no-  
8       tice, that—

9           “(i) the finished product may be  
10       harmful based on adverse event reports or  
11       other scientific information; or

12          “(ii) scientific information raises cred-  
13       ible and relevant questions about the safe-  
14       ty of the product or any of its ingredients;

15          “(B) the Food and Drug Administration,  
16       an expert regulatory body, or an expert body  
17       composed of scientific and medical experts finds  
18       an ingredient in the product to be unsafe under  
19       the conditions of use of the product; or

20          “(C) the Food and Drug Administration  
21       concludes that submission of the records will  
22       serve the public health or otherwise enable the  
23       Food and Drug Administration to fulfill the  
24       cosmetic safety purposes of this section.”.

1 **“SEC. 611. MANDATORY RECALL AUTHORITY.**

2       “(a) VOLUNTARY PROCEDURES.—If the Food and  
3 Drug Administration determines that there is a reasonable  
4 probability that a cosmetic is adulterated under section  
5 601 or misbranded under section 602 and the use of or  
6 exposure to such cosmetic is likely to cause serious adverse  
7 health consequences or death, the Food and Drug Admin-  
8 istration shall provide the responsible person with an op-  
9 portunity to voluntarily cease distribution and recall such  
10 article.

11       “(b) PREHEARING ORDER TO MANDATORILY CEASE  
12 DISTRIBUTION AND GIVE NOTICE.—

13               “(1) IN GENERAL.—If the responsible person  
14 refuses to or does not voluntarily cease distribution  
15 or recall such cosmetic within the time and in the  
16 manner prescribed by the Food and Drug Adminis-  
17 tration, the Food and Drug Administration may  
18 order such person to—

19                       “(A) immediately cease distribution of  
20 such cosmetic; and

21                       “(B) as applicable, immediately notify all  
22 persons—

23                               “(i) manufacturing, processing, pack-  
24 ing, transporting, holding, receiving, dis-  
25 tributing, or importing and selling such  
26 cosmetic; and

1                   “(ii) to which such cosmetic has been  
2                   distributed, transported, or sold (except  
3                   consumers),

4                   to immediately cease distribution of such cos-  
5                   metic.

6                   “(2) REQUIRED ADDITIONAL INFORMATION.—

7                   “(A) IN GENERAL.—If a cosmetic covered  
8                   by a recall order issued under paragraph (1)(B)  
9                   has been distributed to a warehouse-based  
10                  third-party logistics provider without providing  
11                  such provider sufficient information to know or  
12                  reasonably determine the precise identity of  
13                  such cosmetic covered by a recall order that is  
14                  in its possession, the notice provided by the re-  
15                  sponsible person subject to the order issued  
16                  under paragraph (1)(B) shall include such in-  
17                  formation as is necessary for the warehouse-  
18                  based third-party logistics provider to identify  
19                  the cosmetic.

20                  “(B) RULES OF CONSTRUCTION.—Nothing  
21                  in this paragraph shall be construed—

22                  “(i) to exempt a warehouse-based  
23                  third-party logistics provider from the re-  
24                  quirements of this chapter, including the

1 requirements of this section and section  
2 610; or

3 “(ii) to exempt a warehouse-based  
4 third-party logistics provider from being  
5 the subject of a mandatory recall order.

6 “(3) DETERMINATION TO LIMIT AREAS AF-  
7 FECTED.—If the Food and Drug Administration re-  
8 quires a responsible person to cease distribution  
9 under paragraph (1)(A) of a cosmetic, the Food and  
10 Drug Administration may limit the size of the geo-  
11 graphic area and the markets affected by such ces-  
12 sation if such limitation would not compromise the  
13 public health.

14 “(c) HEARING ON ORDER.—The Food and Drug Ad-  
15 ministration shall provide the responsible party subject to  
16 an order under subsection (b) with an opportunity for an  
17 informal hearing, to be held as soon as possible, but not  
18 later than 2 days after the issuance of the order, on the  
19 actions required by the order and on why the cosmetic that  
20 is the subject of the order should not be recalled.

21 “(d) POST-HEARING RECALL ORDER AND MODIFICA-  
22 TION OF ORDER.—

23 “(1) AMENDMENT OF ORDER.—If, after pro-  
24 viding opportunity for an informal hearing under  
25 subsection (c), the Food and Drug Administration

1 determines that removal of the cosmetic from com-  
2 merce is necessary, the Food and Drug Administra-  
3 tion shall, as appropriate—

4 “(A) amend the order to require recall of  
5 such cosmetic or other appropriate action;

6 “(B) specify a timetable in which the recall  
7 shall occur;

8 “(C) require periodic reports to the Food  
9 and Drug Administration describing the  
10 progress of the recall; and

11 “(D) provide notice to consumers to whom  
12 such cosmetic was, or may have been, distrib-  
13 uted.

14 “(2) VACATING OF ORDER.—If, after such hear-  
15 ing, the Food and Drug Administration determines  
16 that adequate grounds do not exist to continue the  
17 actions required by the order, or that such actions  
18 should be modified, the Food and Drug Administra-  
19 tion shall vacate the order or modify the order.

20 “(e) COOPERATION AND CONSULTATION.—The Food  
21 and Drug Administration shall work with State and local  
22 public health officials in carrying out this section, as ap-  
23 propriate.

1       “(f) PUBLIC NOTIFICATION.—In conducting a recall  
2 under this section, the Food and Drug Administration  
3 shall—

4               “(1) ensure that a press release is published re-  
5 garding the recall, and that alerts and public notices  
6 are issued, as appropriate, in order to provide notifi-  
7 cation—

8                       “(A) of the recall to consumers and retail-  
9 ers to whom such cosmetic was, or may have  
10 been, distributed; and

11                      “(B) that includes, at a minimum—

12                               “(i) the name of the cosmetic subject  
13 to the recall;

14                               “(ii) a description of the risk associ-  
15 ated with such article; and

16                               “(iii) to the extent practicable, infor-  
17 mation for consumers about similar cos-  
18 metics that are not affected by the recall;  
19 and

20               “(2) ensure publication on the Internet website  
21 of the Food and Drug Administration of an image  
22 of the cosmetic that is the subject of the press re-  
23 lease described in paragraph (1), if available.

24       “(g) NO DELEGATION.—The authority conferred by  
25 this section to order a recall or vacate a recall order shall

1 not be delegated to any officer or employee other than the  
2 Commissioner.

3 “(h) EFFECT.—Nothing in this section shall affect  
4 the authority of the Food and Drug Administration to re-  
5 quest or participate in a voluntary recall, or to issue an  
6 order to cease distribution or to recall under any other  
7 provision of this chapter or under the Public Health Serv-  
8 ice Act.”.

9 **SEC. 106. LABELING.**

10 (a) IN GENERAL.—Chapter VI of the Federal Food,  
11 Drug, and Cosmetic Act (21 U.S.C. 361 et seq.), as  
12 amended by section 105, is further amended by adding  
13 at the end the following:

14 **“SEC. 612. LABELING.**

15 “(a) SAFETY REVIEW AND LABELING.—Following a  
16 review of cosmetic ingredients that determines that warn-  
17 ings are required to help ensure safe use of cosmetic prod-  
18 ucts under section 607(d)(5), the Food and Drug Admin-  
19 istration shall require labeling of cosmetics that are not  
20 appropriate for use in the entire population, including  
21 warnings that vulnerable populations, such as children or  
22 pregnant women, should limit or avoid using the product.

23 “(b) COSMETIC PRODUCTS FOR PROFESSIONAL  
24 USE.—

1           “(1) DEFINITION OF PROFESSIONAL.—For pur-  
2           poses of this section, with respect to cosmetics, the  
3           term ‘professional’ means an individual who—

4                   “(A) is licensed by an official State author-  
5                   ity to practice in the field of cosmetology, nail  
6                   care, barbering, or esthetics;

7                   “(B) has complied with all requirements  
8                   set forth by the State for such licensing; and

9                   “(C) has been granted a license by a State  
10                  board or legal agency or legal authority.

11           “(2) LISTING OF INGREDIENTS.—Cosmetic  
12           products used and sold by professionals shall list all  
13           ingredients and warnings, as required for other cos-  
14           metic products under this chapter.

15           “(3) PROFESSIONAL USE LABELING.—In the  
16           case of a cosmetic product intended to be used only  
17           by a professional on account of a specific ingredient  
18           or increased concentration of an ingredient that re-  
19           quires safe handling by trained professionals, the  
20           product shall bear a statement as follows: ‘To be Ad-  
21           ministered Only by Licensed Professionals’.

22           “(c) REQUIREMENTS.—

23                   “(1) DISPLAY.—A warning required under sub-  
24                   section (a) and a statement required under sub-  
25                   section (b)(3) shall be prominently displayed—



1                   “(A) in the primary language used on the  
2                   label; and

3                   “(B) in conspicuous and legible type in  
4                   contrast by typography, layout, or color with  
5                   other material printed or displayed on the label.

6                   “(2) MINIMUM WARNING REQUIREMENTS.—A  
7                   responsible person may include on the labeling any  
8                   additional warnings in addition to the minimum  
9                   warnings required under subsection (a).

10                  “(d) INTERNET SALES.—In the case of Internet sales  
11 of cosmetics, each Internet website offering a cosmetic  
12 product for sale to consumers shall provide the same infor-  
13 mation, in an electronically readable format, that is in-  
14 cluded on the packaging of the cosmetic product as regu-  
15 larly available through in-person sales, except information  
16 that is unique to a single cosmetic product sold in a retail  
17 facility, such as a lot number or expiration date, and the  
18 warnings and statements described in subsection (c) shall  
19 be prominently and conspicuously displayed on the  
20 website.

21                  “(e) CONTACT INFORMATION.—The label on each  
22 cosmetic shall bear the manufacturer’s toll-free domestic  
23 telephone number and electronic contact information, and  
24 it is encouraged that the label include both the telephone  
25 number and electronic contact information, that con-

1 consumers may use to contact the responsible person with re-  
2 spect to adverse events. The contact number shall provide  
3 a means for consumers to obtain additional information  
4 about ingredients in the designated cosmetic, including the  
5 ability to ask if a specific ingredient may be present that  
6 is not listed on the label and whether a specific ingredient  
7 may be contained in the fragrance or flavor used in the  
8 cosmetic. The manufacturer of the cosmetic is responsible  
9 for providing such information, including obtaining the in-  
10 formation from suppliers if it is not readily available. Sup-  
11 pliers are required to release such information upon re-  
12 quest of the cosmetic manufacturer.”.

13 (b) USE OF THE TERM “NATURAL” IN LABELING.—  
14 The Food and Drug Administration—

15 (1) in consultation with consumer protection  
16 stakeholders and the scientific community, shall es-  
17 tablish a definition of the term “natural” with re-  
18 spect to the use of such term in the labeling of cos-  
19 metics;

20 (2) not later than 1 year after the date of en-  
21 actment of this Act, shall issue proposed regulations  
22 setting forth such definition; and

23 (3) not later than 2 years after such date of en-  
24 actment, issue final regulations setting forth such  
25 definition.

1 (c) EFFECTIVE DATE.—Section 612 of the Federal  
2 Food, Drug, and Cosmetic Act, as added by subsection  
3 (a), shall take effect on the date that is 1 year after the  
4 date of enactment of this Act.

5 **SEC. 107. COAL TAR CHEMICALS.**

6 Chapter VI of the Federal Food, Drug, and Cosmetic  
7 Act (21 U.S.C. 361 et seq.), as amended by section 106,  
8 is further amended by adding at the end the following:

9 **“SEC. 613. COAL TAR CHEMICALS.**

10 “Specific ingredients in coal tar hair dyes may be se-  
11 lected and reviewed under section 607. If the Food and  
12 Drug Administration reviews a coal-tar ingredient found  
13 in hair dye and makes a safety determination under sec-  
14 tion 607(d) for such ingredient, such determination shall  
15 include consideration for the safe use of such ingredient  
16 through appropriate conditions of use, which may include  
17 a specific label requirement, specified limits of concentra-  
18 tions, or other such conditions of use as the Food and  
19 Drug Administration determines appropriate, including a  
20 finding of not safe under any conditions if appropriate.”.

21 **SEC. 108. FRAGRANCE ALLERGEN DISCLOSURE.**

22 (a) IN GENERAL.—Chapter VI of the Federal Food,  
23 Drug, and Cosmetic Act (21 U.S.C. 361 et seq.), as  
24 amended by section 107, is further amended by adding  
25 at the end the following:

1 **“SEC. 614. FRAGRANCE ALLERGENS.**

2 “(a) FRAGRANCE ALLERGENS.—Not later than 2  
3 years after the date of enactment of the Personal Care  
4 Products Safety Act, the responsible person shall include  
5 on the label of any cosmetic product containing one or  
6 more fragrance allergens, a list of each such fragrance al-  
7 lergen present in a rinse-off cosmetic at a concentration  
8 above 0.01 percent (100 ppm) or present in a leave-on  
9 cosmetic product at a concentration above .001 percent  
10 (10 ppm), in a form and manner as specified by the Food  
11 and Drug Administration.”.

12 “(b) IDENTIFIED FRAGRANCE ALLERGENS.—The  
13 fragrance allergens required to be identified on a label of  
14 a cosmetic product pursuant to subsection (a) include—

- 15 “(1) alpha-Isomethyl ionone;  
16 “(2) amyl cinnamal;  
17 “(3) amylcinnamyl alcohol;  
18 “(4) anise alcohol;  
19 “(5) benzyl alcohol;  
20 “(6) benzyl benzoate;  
21 “(7) benzyl cinnamate;  
22 “(8) benzyl salicylate;  
23 “(9) butylphenyl methylpropional;  
24 “(10) cinnamal;  
25 “(11) cinnamyl alcohol;  
26 “(12) citral;

- 1           “(13) citronellol;
- 2           “(14) coumarin;
- 3           “(15) eugenol;
- 4           “(16) evernia prunastri (oak moss);
- 5           “(17) evernia furfuracea (tree moss);
- 6           “(18) farnesol;
- 7           “(19) geraniol;
- 8           “(20) hexyl cinnamal;
- 9           “(21) hydroxycitronellal;
- 10          “(22)           hydroxyisohexyl           3-cyclohexene
- 11          carboxaldehyde;
- 12          “(23) isoeugenol;
- 13          “(24) limonene;
- 14          “(25) linalool;
- 15          “(26) methyl 2-octynoate; and
- 16          “(27) other substances as identified by the
- 17          Food and Drug Administration in guidance issued
- 18          pursuant to this section.
- 19          “(c) GUIDANCE.—
- 20                 “(1) ISSUANCE.—Not later than one year after
- 21          the date of enactment of the Personal Care Products
- 22          Safety Act, the Food and Drug Administration shall
- 23          issue guidance specifying the form and manner of
- 24          fragrance allergen listing on the label of cosmetic
- 25          products pursuant to subsection (a).

1           “(2) CONTENT.—The guidance described in  
2 paragraph (1) shall—

3           “(A) specify the form and manner of fra-  
4 grance allergen listing for cosmetic products  
5 where the package or label is too small or oth-  
6 erwise is unable to accommodate a label with  
7 sufficient space to bear the information re-  
8 quired for compliance with this section; and

9           “(B) take into consideration requirements  
10 under international regulations for fragrance al-  
11 lergen labeling, as appropriate.

12           “(3) UPDATES.—The Food and Drug Adminis-  
13 tration may, as appropriate, update the list of fra-  
14 grance allergens to include additional substances  
15 pursuant to guidance issued under this subsection  
16 and taking into consideration international regula-  
17 tions, as appropriate.

18           “(d) CONTACT INFORMATION.—

19           “(1) IN GENERAL.—The contact information on  
20 the label on a cosmetic product for consumers to re-  
21 port adverse events shall also provide a means for  
22 consumers to obtain additional information about  
23 the inclusion of any recognized fragrance allergen  
24 required to be included on such label under sub-  
25 section (a).

1           “(2) RESPONSE.—

2                   “(A) IN GENERAL.—The responsible per-  
3           son shall—

4                           “(i) upon receipt of a request for in-  
5                           formation under paragraph (1), promptly  
6                           obtain and provide such information to the  
7                           requesting consumer; and

8                           “(ii) in the case of information in the  
9                           possession of a supplier, promptly obtain  
10                          such information from such supplier, if  
11                          reasonably available.

12                          “(B) SUPPLIER.—A relevant supplier shall  
13                          promptly provide information requested to a re-  
14                          sponsible person pursuant to subparagraph  
15                          (A)(ii).”.

16           (b) INGREDIENT STATEMENT.—Section 602 of the  
17           Federal Food, Drug, and Cosmetic Act (21 U.S.C. 362),  
18           as amended by section 114(c), is further amended by add-  
19           ing at the end the following:

20                   “(i) If its labeling or packaging does not contain a  
21                   listing of ingredients that meets the requirements of sec-  
22                   tion 614.”.

23           (c) EFFECTIVE DATE.—The amendments made by  
24           this section shall apply with respect to cosmetics intro-  
25           duced or delivered for introduction into interstate com-

1 merce on or after the date that is 2 years after the date  
2 of enactment of this Act.

3 **SEC. 109. SENSE OF THE SENATE ON ANIMAL TESTING.**

4 (a) ANIMAL TESTING.—Chapter VI of the Federal  
5 Food, Drug, and Cosmetic Act (21 U.S.C. 361 et seq.),  
6 as amended by section 108, is further amended by adding  
7 the following:

8 **“SEC. 615. ANIMAL TESTING.**

9 “It is the sense of the Senate that animal testing  
10 should not be used for the purposes of safety testing on  
11 cosmetic products and should be phased out with the ex-  
12 ception of appropriate allowances.”.

13 **SEC. 110. PREEMPTION.**

14 Chapter VI of the Federal Food, Drug, and Cosmetic  
15 Act (21 U.S.C. 361 et seq.), as amended by section 109,  
16 is further amended by adding the following:

17 **“SEC. 616. PREEMPTION.**

18 “(a) IN GENERAL.—No State or political subdivision  
19 of a State may establish or continue in effect any require-  
20 ment for cosmetics, other than a requirement that is in  
21 full effect and implemented on the date of enactment of  
22 the Personal Care Products Safety Act—

23 “(1) with respect to registration, good manufac-  
24 turing practices, mandatory recalls, or adverse event  
25 reporting; or



1           “(2) with respect to the safety of a cosmetic in-  
2           ingredient or non-functional constituent that is the  
3           subject of a final order on a determination of safety  
4           under this chapter, unless the requirement of the  
5           State or political subdivision is more restrictive than  
6           the final order under section 607(d)(3).

7           “(b) SAFETY OF COSMETIC INGREDIENTS AND NON-  
8           FUNCTIONAL CONSTITUENTS.—

9           “(1) DELAYED EFFECT OF NEW STATE RE-  
10          QUIREMENTS.—

11           “(A) IN GENERAL.—From the date that  
12          the Food and Drug Administration has made  
13          public the final selection of a cosmetic ingre-  
14          dient or non-functional constituent to be re-  
15          viewed in the coming year under section  
16          607(a)(3) and opened the public comment pe-  
17          riod under section 607(a)(2), until the date that  
18          is one year after the Food and Drug Adminis-  
19          tration has made public such selection, no State  
20          or political subdivision of a State may establish  
21          any new requirement related to such cosmetic  
22          ingredient or non-functional constituent.

23           “(B) INITIAL REVIEW.—With respect to  
24          the cosmetic ingredients to be reviewed in the  
25          first year, in accordance with section 607(a)(3),

1           for the 1-year period beginning on the date that  
2           is 6 months after the date of enactment of the  
3           Personal Care Products Safety Act, no State or  
4           political subdivision of a State may establish  
5           any new requirement related to such cosmetic  
6           ingredient or non-functional constituent.

7           “(2) SCOPE.—Subsection (a)(2) shall not be  
8           construed to affect the authority of a State or polit-  
9           ical subdivision of a State with respect to any re-  
10          quirement for the safety of a cosmetic ingredient or  
11          non-functional constituent that is unrelated to the  
12          scope of the safety assessment under section 607.

13          “(3) SENSE OF CONGRESS.—It is the sense of  
14          Congress that a State or political subdivision that  
15          regulates the safety of cosmetics with respect to the  
16          health of humans beyond the scope of section 607  
17          should utilize the safety assessment criteria de-  
18          scribed in section 607(h).

19          “(c) STATE REQUIREMENT THAT IS IN FULL EF-  
20          FECT AND IMPLEMENTED.—For purposes of this section:

21                 “(1) STATE REQUIREMENT.—A State require-  
22                 ment includes a State requirement that is adopted  
23                 by a State public initiative or referendum.

24                 “(2) FULL EFFECT AND IMPLEMENTED.—The  
25                 term ‘full effect and implemented’ includes require-

1       ments of States that are implemented after the date  
2       of enactment of the Personal Care Products Safety  
3       Act, if such requirements are under a law that was  
4       in effect, or a lawful program that was established  
5       and functioning, prior to the date of enactment of  
6       the Personal Care Products Safety Act.

7       “(d) LIMITATION.—Nothing in the amendments to  
8       this Act made by the Personal Care Products Safety Act  
9       shall be construed to preempt any State statute, public  
10      initiative, referendum, or other State action, except as ex-  
11      pressly provided in this section.

12      “(e) SAVINGS.—Nothing in the amendments to this  
13      Act made by the Personal Care Products Safety Act, nor  
14      any standard, rule, requirement, regulation, adverse event  
15      report, safety assessment, safety determination, scientific  
16      assessment, or order issued or implemented pursuant to  
17      such amendments, shall be construed to modify or other-  
18      wise affect, preempt, or displace any cause of action or  
19      State or Federal law creating a remedy for civil relief or  
20      criminal cause of action, whether statutory or based in  
21      common law.

22      “(f) SENSE OF THE SENATE.—It is the sense of the  
23      Senate that subsection (e) does not negate the other provi-  
24      sions of this section.”.

1 **SEC. 111. REPORTING.**

2 Chapter VI of the Federal Food, Drug, and Cosmetic  
3 Act (21 U.S.C. 361 et seq.), as amended by section 110,  
4 is further amended by adding at the end the following:

5 **“SEC. 617. REPORTING.**

6 “(a) PERFORMANCE REPORT.—Not later than 1 year  
7 after the date of enactment of the Personal Care Products  
8 Safety Act, and not later than 60 days prior to the end  
9 of each fiscal year for which fees are collected under sec-  
10 tion 7440, the Food and Drug Administration shall pre-  
11 pare and submit to Congress a report concerning the  
12 progress of the Food and Drug Administration in achiev-  
13 ing the objectives of the Personal Care Products Safety  
14 Act during such fiscal year and the future plans of the  
15 Food and Drug Administration for meeting the objectives.  
16 The annual report for a fiscal year shall include—

17 “(1) the number of registered facilities and cos-  
18 metic ingredient statements on file with the Food  
19 and Drug Administration;

20 “(2) identification of the cosmetic ingredients  
21 and non-functional constituents that have been fully  
22 reviewed for safety by the Food and Drug Adminis-  
23 tration in the prior fiscal year and for which a final  
24 administrative order has been released;

25 “(3) identification of at least 5 specific cosmetic  
26 ingredients and non-functional constituents that will

1 be reviewed by the Food and Drug Administration  
2 in the next fiscal year;

3 “(4) the number of facilities inspected and  
4 mandatory recalls that transpired during that fiscal  
5 year;

6 “(5) the number of serious adverse event re-  
7 ports received by the Food and Drug Administration  
8 during that fiscal year; and

9 “(6) any trends identified by the Food and  
10 Drug Administration about adverse event reports re-  
11 lated to specific cosmetic ingredients or non-func-  
12 tional constituents.

13 “(b) PUBLIC AVAILABILITY.—The Food and Drug  
14 Administration shall make the reports required under sub-  
15 section (a) available to the public on the Internet website  
16 of the Food and Drug Administration on the date of sub-  
17 mission of such reports to Congress.

18 “(c) PUBLIC INPUT ON SAFETY REVIEW.—Upon re-  
19 lease of the report described in subsection (a), the Food  
20 and Drug Administration shall provide the public with an  
21 opportunity to provide feedback, at any time during the  
22 year, on the identification of ingredients under subsection  
23 (a)(3) by—

24 “(1) providing an electronic portal, upon release  
25 of the report, enabling the public to—

1           “(A) comment on the cosmetic ingredients  
2           or non-functional constituents under review for  
3           the current year;

4           “(B) recommend additional cosmetic ingre-  
5           dients and non-functional constituents to be  
6           considered for review for safety in future years;  
7           and

8           “(C) comment on the priorities for the spe-  
9           cific cosmetic ingredients and non-functional  
10          constituents that the Food and Drug Adminis-  
11          tration anticipates will be reviewed in the next  
12          fiscal year;

13          “(2) announcing on the Internet website of the  
14          Food and Drug Administration, within the first 30  
15          days of the new fiscal year, any amendments to the  
16          list of cosmetic ingredients and non-functional con-  
17          stituents submitted pursuant to subsection (a)(3)  
18          based on public input, pursuant to paragraph (1);  
19          and

20          “(3) together with the final announcement of at  
21          least 5 specific cosmetic ingredients and non-func-  
22          tional constituents that will be reviewed in the com-  
23          ing year under section 607, providing a comment pe-  
24          riod for further public input, pursuant to section  
25          607(a)(2).”.

1 **SEC. 112. SMALL BUSINESSES.**

2 Chapter VI of the Federal Food, Drug, and Cosmetic  
3 Act (21 U.S.C. 361 et seq.), as amended by section 111,  
4 is further amended by adding at the end the following:

5 **“SEC. 618. SMALL BUSINESSES.**

6 “The Commissioner, in coordination with the Admin-  
7 istrator of the Small Business Administration, shall pro-  
8 vide technical assistance, such as guidance and expertise,  
9 to small businesses regarding compliance with the Per-  
10 sonal Care Products Safety Act, including the amend-  
11 ments made by such Act.”.

12 **SEC. 113. APPLICABILITY WITH RESPECT TO CERTAIN COS-**  
13 **METICS.**

14 Chapter VI of the Federal Food, Drug, and Cosmetic  
15 Act (21 U.S.C. 361 et seq.), as amended by section 112,  
16 is further amended by adding at the end the following:

17 **“SEC. 619. APPLICABILITY WITH RESPECT TO CERTAIN**  
18 **COSMETICS.**

19 “In the case of a cosmetic product or a facility that  
20 is subject to the requirements under this chapter and  
21 chapter V, if any requirement under chapter V with re-  
22 spect to such cosmetic or facility is substantially similar  
23 to a requirement under this chapter, the cosmetic product  
24 or facility shall be deemed to be in compliance with the  
25 applicable requirement under this chapter if such product  
26 or facility is in compliance with such substantially similar

1 requirement under chapter V, provided that the product  
2 or facility has not obtained a waiver from the requirement  
3 under chapter V. In the case of a cosmetic product or fa-  
4 cility that is subject to, and in compliance with, a fee  
5 under subchapter C of chapter VII, other than a fee under  
6 part 11 of such subchapter, any fee under such part 11  
7 shall be waived with respect to such cosmetic product or  
8 facility (with respect to cosmetic products).”.

9 **SEC. 114. ENFORCEMENT.**

10 (a) PROHIBITED ACTS.—Section 301 of the Federal  
11 Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amend-  
12 ed—

13 (1) in paragraph (e)—

14 (A) by striking “504, 564,” and inserting  
15 “504, 564, 609, 610,”; and

16 (B) by striking “519, 564,” and inserting  
17 “519, 564, 609,”;

18 (2) in paragraph (j), by inserting “606, 607,  
19 608,” before “704”;

20 (3) in paragraph (ii)—

21 (A) by striking “760 or 761) or” and in-  
22 sserting “604, 760, or 761) or”; and

23 (B) by striking “761) submitted” and in-  
24 sserting “761 or as described in section 609)  
25 submitted”;



1           (4) in paragraph (xx) by inserting “or 611”  
2           after “423”; and

3           (5) by adding at the end the following:

4           “(fff) The failure to register in accordance with sec-  
5           tion 605, the failure to provide any information required  
6           by section 605, or the failure to update the information  
7           required by section 605, as required.”.

8           (b) ADULTERATION.—Section 601 of the Federal  
9           Food, Drug, and Cosmetic Act (21 U.S.C. 361) is amend-  
10          ed by adding at the end the following:

11          “(f) If the methods used in, or the facilities or con-  
12          trols used for, its manufacture, processing, packing, or  
13          holding do not conform to current good manufacturing  
14          practice, as prescribed by the Food and Drug Administra-  
15          tion in accordance with section 608.

16          “(g) If it contains, after the date prescribed under  
17          section 607(e), an ingredient that the Food and Drug Ad-  
18          ministration has determined under section 607(d)(4) to be  
19          not safe, or not safe under the conditions of use rec-  
20          ommended or suggested in the label or a non-functional  
21          constituent that the Food and Drug Administration has  
22          determined under section 607(d)(4) to be not safe or not  
23          safe in the amount present in the cosmetic.

1 “(h) If it is a cosmetic product for which assurances  
2 regarding safety substantiation have not been supplied  
3 under section 605(e)(2)(A)(xii).”.

4 (c) MISBRANDING.—Section 602 of the Federal  
5 Food, Drug, and Cosmetic Act (21 U.S.C. 362) is amend-  
6 ed—

7 (1) in paragraph (b)—

8 (A) by striking “and (2)” and inserting  
9 “(2)”; and

10 (B) by inserting “; and (3) a domestic ad-  
11 dress or a domestic telephone number, and it is  
12 encouraged that the label include both a domes-  
13 tic address and a domestic telephone number,  
14 through which the responsible person may re-  
15 ceive a report of an adverse event associated  
16 with the use of such cosmetic product” after  
17 “numerical count”; and

18 (2) by adding at the end the following:

19 “(g) If it has been manufactured or processed in any  
20 factory, warehouse, or establishment and the responsible  
21 person, operator, or agent of such factory, warehouse, or  
22 establishment delays, denies, or limits an inspection, or  
23 refuses to permit entry or inspection.

24 “(h) If its labeling does not conform with a require-  
25 ment under section 612.”.

1 (d) GUIDANCE.—Not later than 1 year after the date  
2 of enactment of this Act, the Food and Drug Administra-  
3 tion shall issue guidance that defines the circumstances  
4 that would constitute delaying, denying, or limiting inspec-  
5 tion, or refusing to permit entry or inspection, for pur-  
6 poses of section 602(g) of the Federal Food, Drug, and  
7 Cosmetic Act, as added by subsection (c)(2).

8 (e) IMPORTS.—Section 801(a) of the Federal Food,  
9 Drug, and Cosmetic Act (21 U.S.C. 381(a)) is amended—

10 (1) by striking “section 760 or 761” the first,  
11 third, and fourth place such term appears and in-  
12 serting “section 609, 760, or 761”; and

13 (2) by striking “760 or 761)” and inserting  
14 “604, 760, or 761)”.

15 (f) FACTORY INSPECTION.—Section 704(a)(1) of the  
16 Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
17 374(a)(1)) is amended by inserting after the third sen-  
18 tence the following: “In the case of any person who manu-  
19 factures, processes, distributes, or imports a cosmetic  
20 product, or distributes a cosmetic product and affixes its  
21 name on the cosmetic label, the inspection shall extend  
22 to all records and other information described in section  
23 610 (regarding inspection of cosmetic records), when the  
24 standard for records inspections under paragraph (1) or  
25 (2) of subsection (a) of such section applies, subject to

1 the limitations under subsections (d) and (e) of such sec-  
2 tion.”.

3 **SEC. 115. CONSUMER INFORMATION.**

4 The Food and Drug Administration shall post on its  
5 Internet website information for consumers regarding—

6 (1) final orders regarding the safety of a cos-  
7 metic ingredient or non-functional constituent under  
8 section 607(d)(3) of the Federal Food, Drug, and  
9 Cosmetic Act;

10 (2) cosmetic product recalls (including vol-  
11 untary and mandatory recalls); and

12 (3) identified counterfeit cosmetic products.

13 **SEC. 116. BAN ON PERFLUOROALKYL OR**  
14 **POLYFLUOROALKYL SUBSTANCES.**

15 Not later than 6 months after the date of enactment  
16 of this Act, the Food and Drug Administration shall issue  
17 a proposed rule to ban the use of intentionally added  
18 perfluoroalkyl or polyfluoroalkyl substances in cosmetics.

19 **SEC. 117. COUNTERFEIT COSMETICS.**

20 (a) COUNTERFEIT COSMETICS DEFINED.—Section  
21 201(i) of the Federal Food, Drug, and Cosmetic Act (21  
22 U.S.C. 321(i)) is amended—

23 (1) by striking “(i) The term” inserting “(i)(1)  
24 The term”;

1           (2) by striking “(1) articles intended to be” and  
2           inserting “(A) articles intended to be”;

3           (3) by striking “(2) articles intended for use”  
4           and inserting “(B) articles intended for use”; and

5           (4) by adding at the end the following:

6           “(2) The term ‘counterfeit cosmetic’ means a cos-  
7           metic which, or the container or labeling of which, without  
8           authorization—

9           “(A) bears the trademark, trade name, or other  
10          identifying mark, imprint, or device, or any likeness  
11          thereof, of a cosmetic manufacturer, processor, pack-  
12          er, or distributor other than the person or persons  
13          who in fact manufactured, processed, packed, or dis-  
14          tributed such cosmetic; and

15          “(B) thereby falsely purports or is represented  
16          to be the product of, or to have been packed or dis-  
17          tributed by, such other cosmetic manufacturer, proc-  
18          essor, packer, or distributor.”.

19          (b) PROHIBITED ACT.—Section 301(i) of the Federal  
20          Food, Drug, and Cosmetic Act (21 U.S.C. 331(i)) is  
21          amended—

22                 (1) in subparagraph (2)—

23                         (A) by inserting “digital printer,” after  
24                         “stone,”;

1 (B) by inserting “cosmetic” after “drug  
2 or”; and

3 (C) by inserting before the period at the  
4 end the following: “or such cosmetic a counter-  
5 feit cosmetic”; and

6 (2) in subparagraph (3)—

7 (A) by inserting “or a cosmetic to be a  
8 counterfeit cosmetic” after “to be a counterfeit  
9 drug”; and

10 (B) by inserting “or counterfeit cosmetic”  
11 before the period at the end.

12 (c) PENALTIES.—Section 303(c)(5) of the Federal  
13 Food, Drug, and Cosmetic Act (21 U.S.C. 333(c)(5)) is  
14 amended—

15 (1) by inserting “digital printer” after “stone,”;

16 (2) by inserting “or a cosmetic being a counter-  
17 feit cosmetic” after “drug being a counterfeit drug”;

18 and

19 (3) by inserting before the period at the end the  
20 following: “or the cosmetic was a counterfeit cos-  
21 metic”.

22 (d) SEIZURE.—Section 304(a)(2) of the Federal  
23 Food, Drug, and Cosmetic Act (21 U.S.C. 334(a)(2)) is  
24 amended—

1           (1) by striking “(B) Any container” and all  
2           that follows through “(D) Any adulterated” and in-  
3           serting “(B) Any cosmetic that is a counterfeit cos-  
4           metic, (C) Any container of a counterfeit drug or  
5           counterfeit cosmetic, (D) Any punch, die, plate,  
6           stone, labeling, container, digital printer, or other  
7           thing used or designed for use in making a counter-  
8           feit drug or drugs or a counterfeit cosmetic or cos-  
9           metics, (E) Any adulterated”; and

10           (2) by striking “(E)” and inserting “(F)” be-  
11           fore “Any adulterated or misbranded tobacco prod-  
12           uct”.

13           (e) EXAMINATIONS AND INVESTIGATIONS.—Section  
14           702(e) of the Federal Food, Drug, and Cosmetic Act (21  
15           U.S.C. 372(e)) is amended—

16           (1) in the matter preceding paragraph (1), by  
17           inserting “or counterfeit cosmetics” after “counter-  
18           feit drugs”;

19           (2) in paragraph (4), by inserting “or cos-  
20           metics” after “such drugs”; and

21           (3) in paragraph (5)—

22                   (A) by striking “drugs or containers” and  
23                   inserting “drugs, cosmetics, or containers”; and

24                   (B) by inserting “digital printers,” after  
25                   “labeling,”.

1           **TITLE II—FEES RELATED TO**  
2                           **COSMETIC SAFETY**

3   **SEC. 201. FINDINGS.**

4           Congress finds that the fees authorized by the  
5 amendments made by this title will be dedicated to cos-  
6 metic safety activities, as set forth in the goals identified  
7 for purposes of part 11 of subchapter C of chapter VII  
8 of the Federal Food, Drug, and Cosmetic Act, in the let-  
9 ters from the Secretary of Health and Human Services  
10 to the Chairman of the Committee on Health, Education,  
11 Labor, and Pensions of the Senate and the Chairman of  
12 the Committee on Energy and Commerce of the House  
13 of Representatives, as set forth in the Congressional  
14 Record.

15   **SEC. 202. AUTHORITY TO ASSESS AND USE COSMETIC SAFE-**  
16                           **TY FEES.**

17           Subchapter C of chapter VII of the Federal Food,  
18 Drug, and Cosmetic Act (21 U.S.C. 379f et seq.) is  
19 amended by adding at the end the following:

20           **“PART 11—FEES RELATING TO COSMETICS**

21   **“SEC. 7440. REGISTRATION FEE.**

22           “(a) ASSESSMENT AND COLLECTION.—

23                   “(1) IN GENERAL.—Beginning in fiscal year  
24           2022, the Food and Drug Administration shall as-  
25           sess and collect an annual fee from every responsible



1 person (referred to in this section as a ‘registrant’)  
2 who owns or operates any facility (as defined in sec-  
3 tion 604(3)) engaged in manufacturing or proc-  
4 essing, or whose name and address appear on the  
5 label of a cosmetic product distributed in the United  
6 States, except that this subsection shall not apply to  
7 contract manufacturers if a responsible person has  
8 already paid the appropriate fee with respect to the  
9 cosmetic product, to ensure no double fees are paid.

10 “(2) PAYABLE DATE.—A fee under this section  
11 shall be payable during the period of initial registra-  
12 tion and on the date of registration each year there-  
13 after as prescribed in section 605(a)(1).

14 “(b) DEFINITIONS.—In this section:

15 “(1) ADJUSTMENT FACTOR.—The term ‘adjust-  
16 ment factor’ applicable to a fiscal year means the  
17 Consumer Price Index for all urban consumers (all  
18 items; United States city average) for October of the  
19 preceding fiscal year divided by such index for Octo-  
20 ber 2021.

21 “(2) AFFILIATE.—The term ‘affiliate’ means  
22 any business entity that has a relationship with a  
23 second business entity if, directly or indirectly—

24 “(A) one business entity controls, or has  
25 power to control, the other business entity; or

1           “(B) a third party controls, or has the  
2           power to control, both of the business entities.

3           “(3) COSMETIC PRODUCT.—The term ‘cosmetic  
4           product’ has the meaning given such term in section  
5           604(2).

6           “(4) COSMETIC SAFETY ACTIVITIES.—The term  
7           ‘cosmetic safety activities’—

8           “(A) means activities related to compliance  
9           by registrants under section 605 with the re-  
10          quirements of this Act with respect to cos-  
11          metics, including—

12                 “(i) administrative activities, such as  
13                 information technology support, human re-  
14                 sources, financial management, the admin-  
15                 istration and maintenance of the cosmetic  
16                 registration system and the cosmetic ingre-  
17                 dient statement system under section 605,  
18                 and fee assessment and collection under  
19                 this section; and

20                 “(ii) implementation and enforcement  
21                 activities, such as the establishment of  
22                 good manufacturing practices, the review  
23                 of adverse event reports, inspection plan-  
24                 ning and inspections, and use of enforce-  
25                 ment tools; and

1           “(B) includes activities related to imple-  
2           mentation of section 607, regarding the review  
3           of cosmetic ingredients and non-functional con-  
4           stituents.

5           “(5) GROSS ANNUAL SALES.—The term ‘gross  
6           annual sales’ means the average United States gross  
7           annual sales for the previous 3-year period of cos-  
8           metics for a registrant, including the sales of all of  
9           its affiliates, as reported in the registration under  
10          section 605.

11          “(c) FEE SETTING AND AMOUNTS.—

12           “(1) IN GENERAL.—Subject to subsection (d),  
13           the Food and Drug Administration shall establish  
14           the fees to be collected under this section for each  
15           fiscal year after fiscal year 2022, based on the meth-  
16           odology described in paragraph (3), and shall pub-  
17           lish such fees in a Federal Register notice not later  
18           than 60 days before the beginning of each such fis-  
19           cal year.

20           “(2) FEE EXEMPTION.—Any registrant whose  
21           gross annual sales of cosmetic products in the 3-year  
22           period immediately preceding the fiscal year for  
23           which the annual fee will be paid was not more than  
24           \$10,000,000, shall be exempt from registration fees  
25           under this section for that fiscal year.

1           “(3) ANNUAL FEE SETTING.—For fiscal years  
2           2022 through 2027, to generate a total estimated  
3           annual revenue amount of \$20,600,000, the amount  
4           of the registration fee under subsection (a) shall be  
5           as follows:

6                   “(A) TIER I–A.—For a registrant that has  
7                   gross annual sales of \$5,000,000,000 or more  
8                   in 2020, \$1,350,000.

9                   “(B) TIER I–B.—For a registrant that has  
10                  gross annual sales of at least \$4,000,000,000  
11                  per annum but less than \$5,000,000,000 in  
12                  2020, \$850,000.

13                  “(C) TIER II–A.—For a registrant that has  
14                  gross annual sales of at least \$3,000,000,000  
15                  per annum but less than \$4,000,000,000 in  
16                  2020, \$730,000.

17                  “(D) TIER II–B.—For a registrant that  
18                  has gross annual sales of at least  
19                  \$2,000,000,000 per annum but less than  
20                  \$3,000,000,000 in 2020, \$610,000.

21                  “(E) TIER III–A.—For a registrant that  
22                  has gross annual sales of at least  
23                  \$1,000,000,000 per annum but less than  
24                  \$2,000,000,000 in 2020, \$500,000.

1           “(F) TIER III–B.—For a registrant that  
2           has gross annual sales of at least \$500,000,000  
3           per annum but less than \$1,000,000,000 in  
4           2020, \$395,000.

5           “(G) TIER IV–A.—For a registrant that  
6           has gross annual sales of at least \$200,000,000  
7           per annum but less than \$500,000,000 in 2020,  
8           \$325,000.

9           “(H) TIER IV–B.—For a registrant that  
10          has gross annual sales of at least \$100,000,000  
11          per annum but less than \$200,000,000 in 2020,  
12          \$275,000.

13          “(I) TIER V–A.—For a registrant that has  
14          gross annual sales of at least \$80,000,000 per  
15          annum but less than \$100,000,000 in 2020,  
16          \$185,000.

17          “(J) TIER V–B.—For a registrant that has  
18          gross annual sales of at least \$60,000,000 per  
19          annum but less than \$80,000,000 in 2020,  
20          \$95,000.

21          “(K) TIER VI–A.—For a registrant that  
22          has gross annual sales of at least \$40,000,000  
23          per annum but less than \$60,000,000 in 2020,  
24          \$15,000.

1           “(L) TIER IV–B.—For a registrant that  
2           has gross annual sales of at least \$20,000,000  
3           per annum but less than \$40,000,000 in 2020,  
4           \$12,000.

5           “(M) TIER VII–A.—For a registrant that  
6           has gross annual sales of at least \$10,000,000  
7           per annum but less than \$20,000,000 in 2020,  
8           \$500.

9           “(d) ADJUSTMENTS.—

10           “(1) INFLATION ADJUSTMENT.—

11           “(A) IN GENERAL.—For fiscal year 2023  
12           and each subsequent fiscal year, the revenues  
13           and fee amounts under subsection (c)(3) shall  
14           be adjusted by the Food and Drug Administra-  
15           tion in the annual Federal Register notice es-  
16           tablishing fees in subsection (c)(1), by an  
17           amount equal to the sum of—

18           “(i) one;

19           “(ii) the average annual percent  
20           change in the cost, per full-time equivalent  
21           position of the Food and Drug Administra-  
22           tion, of all personnel compensation and  
23           benefits paid with respect to such positions  
24           for the first 3 of the preceding 4 fiscal  
25           years for which data are available, multi-

1           plied by the average proportion of per-  
2           sonnel compensation and benefits costs to  
3           total Food and Drug Administration costs  
4           for the first 3 years of the preceding 4 fis-  
5           cal years for which data are available; and

6           “(iii) the average annual percent  
7           change that occurred in the Consumer  
8           Price Index for urban consumers (Wash-  
9           ington-Baltimore, DC6 MD-VA-WV; not  
10          seasonally adjusted; all items less food and  
11          energy; annual index) for the first 3 years  
12          of the preceding 4 years for which data are  
13          available multiplied by the average propor-  
14          tion of all costs other than personnel com-  
15          pensation and benefits costs to total Food  
16          and Drug Administration costs for the  
17          first 3 years of the preceding 4 fiscal years  
18          for which data are available.

19          “(B) COMPOUNDED BASIS.—The adjust-  
20          ment made each fiscal year under this sub-  
21          section shall be added on a compounded basis  
22          to the sum of all adjustments made each fiscal  
23          year after fiscal year 2022 under this sub-  
24          section.

1           “(2) FINAL YEAR ADJUSTMENT.—For fiscal  
2           year 2027, the Food and Drug Administration may,  
3           in addition to adjustments under paragraph (1), fur-  
4           ther increase the fee revenues and fees established in  
5           subsection (c) if such an adjustment is necessary to  
6           provide for not more than 3 months of operating re-  
7           serves of carryover fees for cosmetic safety activities  
8           for the first 3 months of fiscal year 2028. If such  
9           an adjustment is necessary, the rationale for the in-  
10          crease, shall be contained in the annual Federal  
11          Register notice establishing fees, in subsection  
12          (c)(1), for fiscal year 2027. If the Food and Drug  
13          Administration has carryover balances for such ac-  
14          tivities in excess of 3 months of such operating re-  
15          serves, the adjustment under this subparagraph  
16          shall not be made.

17           “(3) WORKLOAD ADJUSTMENT.—

18           “(A) IN GENERAL.—For fiscal year 2023  
19           and each subsequent fiscal year, after fee reve-  
20           nues established in subsection (c)(3) are ad-  
21           justed for a fiscal year for inflation in accord-  
22           ance with paragraph (1), the fee revenues shall  
23           be adjusted further for each fiscal year to re-  
24           flect changes in the workload of the Food and  
25           Drug Administration for actual changes in



1 workload volume due to the process of reviewing  
2 cosmetic ingredients or non-functional constitu-  
3 ents not listed under section 607(b).

4 “(B) DETERMINATION OF ADJUSTMENT.—  
5 The adjustment shall be determined by the  
6 Food and Drug Administration based on the  
7 workload in the most recent 1-year period for  
8 which workload data is available. The Food and  
9 Drug Administration shall publish in the Fed-  
10 eral Register the fee revenues and fees resulting  
11 from the adjustment and the supporting meth-  
12 odologies.

13 “(C) MINIMUM REVENUES.—The adjust-  
14 ment shall not result in fee revenues for a fiscal  
15 year that are less than the sum of the amount  
16 under subsection (c)(3), as adjusted for infla-  
17 tion under subparagraph (1).

18 “(e) LIMITATIONS.—

19 “(1) IN GENERAL.—With respect to the amount  
20 that, under the salaries and expenses account of the  
21 Food and Drug Administration, is appropriated for  
22 a fiscal year for the cosmetics program in the Center  
23 for Food Safety and Applied Nutrition and related  
24 field activities, fees may not be assessed under sub-  
25 section (a) for the fiscal year unless the amount so

1       appropriated for the fiscal year (excluding the  
2       amount of fees appropriated for the fiscal year), is  
3       equal to or greater than that assessed for fiscal year  
4       2021, multiplied by the adjustment factor applicable  
5       to the fiscal year involved.

6               “(2) AUTHORITY.—If the Food and Drug Ad-  
7       ministration does not assess fees under subsection  
8       (a) during any portion of a fiscal year because of  
9       paragraph (1) and if at a later date in such fiscal  
10      year the Food and Drug Administration may assess  
11      such fees, the Food and Drug Administration may  
12      assess and collect such fees, without any modifica-  
13      tion in the rate, for registration under section 605  
14      at any time in such fiscal year.

15              “(f) CREDITING AND AVAILABILITY OF FEES.—

16              “(1) IN GENERAL.—Fees authorized under sub-  
17      section (a) shall be collected and available for obliga-  
18      tion only to the extent and in the amount provided  
19      in advance in appropriations Acts. Such fees are au-  
20      thorized to remain available until expended. Such  
21      sums as may be necessary may be transferred from  
22      the Food and Drug Administration salaries and ex-  
23      penses appropriation account without fiscal year lim-  
24      itation to such appropriation account for salaries  
25      and expenses with such fiscal year limitation. The

1        sums transferred shall be available solely for cos-  
2        metic safety activities.

3            “(2)    COLLECTIONS    AND    APPROPRIATIONS  
4        ACTS.—

5            “(A)    IN GENERAL.—Subject to subpara-  
6        graphs (C) and (D), the fees authorized by this  
7        section shall be collected and available in each  
8        fiscal year in an amount not to exceed the  
9        amount specified in appropriation Acts, or oth-  
10       otherwise made available for obligation for such  
11       fiscal year.

12           “(B)    USE OF FEES AND LIMITATION.—  
13        The fees authorized by this section shall be col-  
14       lected and available only to defray the costs of  
15       cosmetic safety activities.

16           “(C)    FEE COLLECTIONS DURING FIRST  
17        PROGRAM YEAR.—Until the date of enactment  
18       of an Act making appropriations through Sep-  
19       tember 30, 2020, for the salaries and expenses  
20       account of the Food and Drug Administration,  
21       fees authorized by this section for fiscal year  
22       2022 may be collected and shall be credited to  
23       such account to remain available until ex-  
24       pended. Fees collected under this subparagraph  
25       shall be considered discretionary for purposes of

1 the Balanced Budget and Emergency Deficit  
2 Control Act of 1985.

3 “(D) REIMBURSEMENT OF START-UP  
4 AMOUNTS.—Any amounts allocated to establish  
5 programs under section 605, prior to collection  
6 of fees, may be reimbursed through any appro-  
7 priated fees collected under this section, in such  
8 manner as the Food and Drug Administration  
9 determines appropriate. Any amounts reim-  
10 bursed under this subparagraph shall be avail-  
11 able for the programs and activities for which  
12 funds allocated to establish the programs were  
13 available, prior to such allocation, until the end  
14 of the fiscal year in which the reimbursement  
15 occurs, notwithstanding any otherwise applica-  
16 ble limits on amounts for such program or ac-  
17 tivities for a fiscal year.

18 “(3) AUTHORIZATION OF APPROPRIATIONS.—  
19 For each of fiscal years 2022 through 2028, there  
20 are authorized to be appropriated for fees under this  
21 section \$20,600,000, as adjusted by subsection (d).

22 “(4) OFFSET OF OVERCOLLECTIONS; RECOVERY  
23 OF COLLECTION SHORTFALLS.—

24 “(A) OFFSET OF OVERCOLLECTIONS.—If  
25 the sum of the cumulative amount of fees col-

1 lected under this section for the fiscal years  
2 2022 through 2026 exceeds the cumulative  
3 amount appropriated pursuant to paragraph (3)  
4 for fiscal years 2022 through 2027, the excess  
5 amount shall be credited to the appropriation  
6 account of the Food and Drug Administration  
7 as provided in paragraph (1), and shall be sub-  
8 tracted from the amount of fees that would oth-  
9 erwise be authorized to be collected under this  
10 section pursuant to appropriation Acts for fiscal  
11 year 2028.

12 “(B) RECOVERY OF COLLECTION SHORT-  
13 FALLS.—

14 “(i) 2024.—For fiscal year 2024, the  
15 amount of fees otherwise authorized to be  
16 collected under this section shall be in-  
17 creased by the amount, if any, by which  
18 the amount collected under this section  
19 and appropriated for fiscal year 2022 falls  
20 below the amount of fees authorized for  
21 fiscal year 2022 under paragraph (3).

22 “(ii) 2025.—For fiscal year 2025, the  
23 amount of fees otherwise authorized to be  
24 collected under this section shall be in-  
25 creased by the amount, if any, by which

1 the amount collected under this section  
2 and appropriated for fiscal year 221 falls  
3 below the amount of fees authorized for  
4 fiscal year 2023 under paragraph (3).

5 “(iii) 2026.—For fiscal year 2026,  
6 the amount of fees otherwise authorized to  
7 be collected under this section shall be in-  
8 creased by the amount, if any, by which  
9 the amount collected under this section  
10 and appropriated for fiscal year 2024 falls  
11 below the amount of fees authorized for  
12 fiscal year 2024 under paragraph (3).

13 “(iv) 2027.—For fiscal year 2027, the  
14 amount of fees otherwise authorized to be  
15 collected under this section shall be in-  
16 creased by the amount, if any, by which  
17 the amount collected under this section  
18 and appropriated for fiscal year 2025 falls  
19 below the amount of fees authorized for  
20 fiscal year 2025 under paragraph (3).

21 “(v) 2028.—For fiscal year 2028, the  
22 amount of fees otherwise authorized to be  
23 collected under this section shall be in-  
24 creased by the amount, if any, by which  
25 the amount collected under this section

1                   and appropriated for fiscal year 2026 falls  
2                   below the amount of fees authorized for  
3                   fiscal year 2026 under paragraph (3).

4           “(g) EFFECT OF FAILURE TO PAY FEES.—The Food  
5 and Drug Administration shall not consider a registration  
6 submitted to be complete until such fee under subsection  
7 (a) is paid. Until the fee is paid, the registration is incom-  
8 plete and the registrant is deemed to have failed to reg-  
9 ister in accordance with section 605.

10           “(h) FALSE STATEMENTS.—Any statement or rep-  
11 resentation made to the Food and Drug Administration  
12 shall be subject to section 1001 of title 18, United States  
13 Code.

14           “(i) COLLECTION OF UNPAID FEES.—In any case  
15 where the Food and Drug Administration does not receive  
16 payment of a fee assessed under subsection (a), such fee  
17 shall be treated as a claim of the United States Govern-  
18 ment subject to subchapter II of chapter 37 of title 31,  
19 United States Code.

20           “(j) CONSTRUCTION.—This section may not be con-  
21 strued to require that the number of full-time equivalent  
22 positions in the Department of Health and Human Serv-  
23 ices, for officers, employees, and advisory committees not  
24 engaged in cosmetic activities, be reduced to offset the

1 number of officers, employees, and advisory committees so  
2 engaged.

3 “(k) RECORDS.—Each facility shall retain all records  
4 necessary to demonstrate the facility’s gross annual sales  
5 for at least 2 fiscal years after such information is re-  
6 ported in the facility’s registration. Such records shall be  
7 made available to the Food and Drug Administration for  
8 review and duplication upon request of the Food and Drug  
9 Administration.”.

10 **SEC. 203. DIRECT HIRING AUTHORITY TO SUPPORT ACTIVI-**  
11 **TIES RELATED TO COSMETICS.**

12 Part 11 of subchapter C of chapter VII of the Fed-  
13 eral Food, Drug, and Cosmetic Act, as added by section  
14 202, is amended by inserting after section 744O the fol-  
15 lowing:

16 **“SEC. 744P. DIRECT HIRING AUTHORITY TO SUPPORT AC-**  
17 **TIVITIES RELATED TO COSMETICS.**

18 “(a) IN GENERAL.—The Food and Drug Administra-  
19 tion shall have direct hiring authority with respect to the  
20 appointment of employees into the competitive service or  
21 the excepted service to administer the amendments made  
22 by title I of the Personal Care Products Safety Act.

23 “(b) SUNSET.—The authority under subsection (a)  
24 shall terminate on the date that is 3 years after the date  
25 of enactment of such title.”.